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INTRODUCTION 
Salivary gland can be divided into three pairs of major salivary gland 
comprising of parotid, submandibular, sublingual and numerous minor salivary 
glands in the oral cavity, floor of mouth, hard and soft palate, tonsil, tongue and 
oropharynx, which produce saliva1. 
Salivary gland neoplasms are rare tumors, they account about less than 
3-10% of head and neck  neoplasms2. The 2005 revised WHO classification  of 
salivary gland tumors account for more than 35 distinct variants of salivary 
gland neoplasms3. 
Salivary gland tumors account about 0.4 to 13 per 1,00,000 patients 
annually4. About 70 - 80% of tumors arise from parotid gland, 7-10% are 
located in submandibular gland, the remaining are in sublingual and other 
minor salivary glands5. 
Among this 70-80% of tumors that arises from parotid, only 15-30% are 
malignant, the rest are benign. The most common benign tumor of parotid 
gland is Pleomorphic adenoma, and the most common malignant tumor is 
Mucoepidermoid carcinoma.  About 50% of tumors that arise from minor 
salivary glands are malignant. Mucoepidermoid carcinoma, Adenoid cystic 
carcinoma and Polymorphous low grade adenocarcinoma are more  common 
malignant tumors of minor salivary glands6. 
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Benign tumors are commonly seen in younger age group, whereas the 
malignant tumors are seen in elderly individuals. Clinically benign tumors are 
indistinguishable from malignant tumors, but some of the malignant tumors 
exhibit rapid increase in size are unencapsulated and fixed to the underlying 
tissue; they present with pain, tenderness, facial nerve palsy, and areas of 
ulceration7. 
Haematoxylin and Eosine (H&E) is considered to be the gold standard 
in diagnosis of salivary gland tumors, but in recent days the advance in 
immunohistochemistry (IHC) play an important role in enhancing the accuracy 
in diagnosis of salivary gland tumors. Immunohistochemistry is useful tool in 
identifying the nature of cell, cell differentiation, cell proliferation and tumor 
protein expression1. 
 
 
 
             
                               
 
                                      
 
  
  
 
 
 
 
 
AIMS AND OBJECTIVES 
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AIM AND OBJECTIVES 
 
1. To find out the incidence of various salivary gland tumors in Karpaga 
Vinayaga  Institute of Medical Sciences and Research Centre. 
 
 
2. To categorize the neoplastic lesions as per the WHO classification. 
 
3. To delineate the histomorphological patterns of salivary gland tumors. 
 
4. To apply immunohistochemistry  to enhance the  diagnostic accuracy of   
salivary gland tumors  where ever indicated.      
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                                REVIEW OF LITERATURE 
SALIVARY GLAND STRUCTURE  
There are three major salivary glands in the oral cavity, they are parotid, 
submandibular, sublingual and numerous minor salivary glands. Of these most 
of the salivary glands are located in the oral cavity, some of them in 
oropharynx, sinonasal tract and in upper respiratory tract8. 
Among these three major salivary glands, parotid is the largest salivary 
gland which is situated anteroinferior to the external ear. The submandibular 
glands are located in the floor of the mouth, inferior to the mandible; the 
sublingual salivary glands are the smallest salivary glands predominantly 
located inferior to the tongue. 
Microscopically salivary glands are covered by capsule and are mainly 
composed of ducts and acini. Salivary glands are mainly composed of two 
main type of cells, the serous cells and the mucin secreting cells. 
Serous secreting cells are pyramidal in shape with an eosinophilic 
cytoplasm composed of secretory granules in the apical region, with round 
basally located nuclei. 
Mucous secreting cells are also pyramidal in shape with mucus filled 
cytoplasm in which the accumulated secretory granules pushes the nucleus to 
the periphery or at the base of the cytoplasm. In some of the salivary glands 
both the serous and  mucous secreting cells are present9. 
Myoepithelial cells are situated enclosing this serous or mucinous acini. 
These myoepithelial cells are flattened or spindle shape, highly contractile and 
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branching, which mainly surround the basement membrane of the acini, these 
cells are also called as basket cells. 
Salivary glands are made up of five different types of ducts, intercalated 
ducts, striated ducts, excretory intralobular ducts, interlobular ducts and 
intralobar ducts. 
The secretory acini empty the secretory products into the intercalated 
duct initially which intern connected with striated duct which exhibit tiny basal 
striations and these striated ducts merge with the large excretory intralobular 
duct which are surrounded by connective tissue fibers, these ducts are lined by 
stratified squamous epithelium or cuboidal or columnar epithelium. The main 
function is to empty the secretory  product saliva into the oral cavity10. 
Salivary gland neoplasms 
Salivary gland neoplasms are relatively infrequent tumors which 
account for less than  2% of all tumors11. 
There is a wide range of heterogeneity noted between the benign and 
malignant tumor of salivary glands, because each tumor exhibit different 
biological behavior12. Its rarity and complexity makes diagnosis challenging. 
The classification of salivary gland tumors is complex, but it is useful with 
regards to the diagnostic, prognostic and therapeutic aspect. 
The diagnosis of salivary gland tumors is made carefully by assessing 
the cellular structure, cell differentiation, stromal component architecture of 
tumor, growth pattern of tumor along with the clinical details. 
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WHO Histological Classification of Tumors of the Salivary 
Glands,  Eveson et al (2005) 
 
BENIGN EPITHELIAL TUMORS 
Pleomorphic adenoma  
Myoepithelioma 
Basal cell adenoma 
Warthin's tumor 
Oncocytoma 
Canalicular adenoma 
Sebaceous adenoma 
Lymphadenoma 
Ductal papillomas 
Inverted ductal papilloma 
Intraductal papilloma 
Sialadenoma papilliferum 
Cystadenoma 
SOFT TISSUE TUMORS 
Hemangioma 
HEMATOLYMPHOID TUMORS 
Hodgkin's lymphoma 
Diffuse large B-cell lymphoma 
Extranodal marginal zone B-cell 
lymphoma 
SECONDARY TUMOR 
 
MALIGNANT EPITHELIAL TUMORS 
Acinic cell carcinoma 
Mucoepidermoid carcinoma 
Adenoid cystic carcinoma 
Polymorphous low-grade adenocarcinoma 
Epithelial-myoepithelial carcinoma 
Clear cell carcinoma, not otherwise specified 
Basal cell adenocarcinoma 
Sebaceous carcinoma 
Sebaceous lymphadenocarcinoma 
Cystadenocarcinoma 
Low-grade cribriform cystadenocarcinoma 
Mucinous adenocarcinoma 
Oncocytic carcinoma 
Salivary duct carcinoma 
Adenocarcinoma, not otherwise specified 
Myoepithelial carcinoma 
Carcinoma ex pleomorphic adenoma 
Carcinosarcoma 
Metastasizing pleomorphic adenoma 
Squamous cell carcinoma 
Small cell carcinoma 
Large cell carcinoma 
Lymphoepithelial carcinoma 
Sialoblastoma  
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Pleomorphic adenoma 
Pleomorphic adenoma is a benign mixed salivary gland tumor, with 
epithelial and myoepithelial differentiation. It is the most common benign  
neoplasm. Majority of the tumor arises from major salivary glands.  Among 
them 80% in parotid, 10% in submandibular glands and only 10% occur in 
minor salivary glands13. 
The mean age of presentation is 46 years with female predominance; 
occasionally seen in childrens. Clinically the tumor present as slow growing 
discrete, multinodular, painless mass which usually occur in lower pole of 
superficial lobe. At rare instant patient complains of facial nerve paralysis due 
to extrinsic compression of   facial nerve or infections 14.  
Grossly the tumor is solitary, encapsulated, round to oval mass, some 
tumors may lack fibrous capsule. External surface is bosselated or smooth. Cut 
surface of the tumor is grey to tan in color, firm in consistency. Focal area may 
be gritty and glistening   representing the chondromyxoid differentiation15 . 
Microscopically Pleomorphic adenoma is a mixed tumor, exhibiting 
both epithelial and myoepithelial differentiation along with variable amount of  
characteristic stroma. Epithelial cells may be cuboidal, basaloid, squamoid. 
Myoepithelial cells are spindle, plasmacytoid or clear cell. 
The tumor cells show variable amount of growth pattern. Ductal 
structure which is lined by inner layer of cuboidal cells or columnar cells with 
vesicular nuclei and a prominent nucleoli, the outer myoepithelial cells may be 
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spindle enveloping the inner epithelial cells. The duct may be empty or contain 
eosinophilic secretions. The tumor cells may be arranged in cords and sheets 
mainly composed of epithelial cells, admixed with myoepithelial cells, lacking 
the ductal structure. 
Occasionally the tumor may show moderate degree of atypia and mitotic 
figures. The stroma may be myxoid, chondroid and hyalinised which are 
usually a product of modified myoepithelial cells16. 
In occasional cases the tumor may show squamous metaplasia with 
keratin pearl formation, sebaceous metaplasia, clear cell change and 
mucoepidermoid like metaplasia17. 
Immunohistochemistry for Pleomorphic adenoma: 
 The luminal cells are positive for CK3, CK6, CK10, CK11, CK13. The 
myoepithelial cells shows positivity for P63, Cytokeratin, S100, Vimentin, 
Glial fibrillary acidic protein (GFAP),  Smooth  Muscle Actin (SMA) 18. 
The differential diagnosis of Pleomorphic adenoma is Polymorphous 
low grade adenocarcinoma, Monomorphic adenoma, Adenoid cystic 
carcinoma, Epithelial myoepithelial carcinoma. 
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Warthin`s tumor 
Warthin`s tumor is otherwise called as Papillary cyst adenoma 
lymphomatosum, Adenolymphoma, Cyst adenolymphoma19.  
It is the second most common benign salivary gland tumor often  
involve the parotid. A very low rate of incidence was noted amongst Asian and 
African population. The tumor is mainly composed of papillary and cystic 
structure which are lined by bilayered epithelium composed of luminal 
oncocytic columnar cells surrounded by basal cells .  
The tumor clinically present as slow growing tumor mass approximately 
measuring  2 to 4 cm in diameter, with fluctuation in size. Tumor is most 
commonly seen in elderly individual with a mean age of 62 years with male 
predominance.  The tumors is strongly associated with heavy smoking, 
radiation exposure and atom bomb survivors20 . 
Grossly the tumor is encapsulated, spherical to ovoid mass. The external 
surface of the tumor may be smooth or bosselated, the cut surface may show 
solid and cystic areas, some of the cystic areas are filled with mucoid and 
gelatinous fluid. 
Microscopically, the tumor exhibit numerous cystic structures lined by 
bilayered epithelium, which are thrown into numerous papillary infoldings. 
The bilayered epithelium are composed of inner luminal oncocytic 
columnar cells the outer abluminal cells are usually cuboidal basal cells or 
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flattened cells. The stroma shows dense infiltrations by lymphocytes, plasma 
cells and few histiocytes. At places lymphocytes form germinal centers21. 
Differential diagnosis of Warthin`s tumor is Papillary cystadenoma 
which lack the lymphoid stroma, Simple benign lymphoepithelial cyst, Cystic 
lymphoid hyperplasia, which lack oncocytic epithelium. The squamous 
metaplastic Warthin`s tumor can be mistaken for Squamous or 
Mucoepidermoid carcinoma particularly in the infarcted cases of Warthin`s 
tumor.  Squamous metaplasia in Warthin`s tumor lacks keratinization. 
However   keratinization   will be prominent feature of Squamous cell 
carcinoma22.  
Myoepithelioma 
Myoepithelioma is a benign salivary gland tumor exclusively composed 
of  tumor cells showing myoepithelial differentiation and they may be spindle, 
plasmacytoid or epithelioid in nature. The tumor cells are arranged in cords, 
sheets and islands.  
Myoepithelioma most commonly arises from parotid gland, palate, and 
submandibular gland with a wide range of the age group from 9 to 85 years 
with a mean age of 55 years. No obvious gender predilection is  noted 23.  
Myoepithelioma clinically present as a slow growing painless mass. 
Occasionally Myoepithelial carcinoma can arise from myoepithelioma24. 
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Grossly, Myoepithelioma is a encapsulated, well circumscribed tumor 
mass approximately measuring 1 to 5 cm in diameter. Cut surface of the tumor 
is tan to white in color. 
Microscopically, the tumor is covered by a fibrous capsule in which the 
cells are arranged in solid sheets, microcystic,  reticular growth pattern. The 
individual cells may be spindle, plasmacytoid, epithelioid or clear cell type. 
The spindle cell have centrally located nuclei arranged in fascicular growth 
pattern, which is the most common  growth pattern; plasmacytoid cells are 
round to oval in shape with eccentrically placed nuclei with eosinophilic 
cytoplasm; they are also called hyaline cells25. 
The epithelial cells are arranged in cords and sheets; they are polygonal 
in shape with a centrally located   nuclei and an eosinophilic cytoplasm. 
The clear cells exhibit abundant glycoprotein which are usually positive 
for Periodic Acid Schiff (PAS). The stroma is usually hyalinized or myxoid. 
Immunohistochemistry 
Myoepithelial cells shows positivity for Pancytokeratin, P63, S100 and 
Vimentin26.  
Differential diagnosis for Myoepithelioma and its variants like Spindle 
cell myoepithelioma should be differentiated from Leiomyoma, Benign fibrous 
histiocytoma;   Plasma cell variants of Myoepithelioma should be differentiated 
from Plasmacytoma. Myoepithelioma should be differentiated from 
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Myoepithelial carcinoma based on the invasion, cellular pleomorphism, 
mitosis, necrosis.  
Basal cell adenoma 
Basal cell adenoma of salivary glands are rare entity which is mainly 
composed of basaloid cells.  Basal cell adenoma most commonly affect parotid 
gland, at rare instances it involves minor salivary glands27. 
The tumor most commonly seen with the mean age of 58 years with 
female predominance. Clinically Basal cell adenoma presents as a superficial, 
freely mobile, solitary tumor mass.  
Grossly it is a well circumscribed tumor mass round to oval in shape; 
cut surface of the mass being a gray white in color and  firm in consistency. 
Microscopically   the tumor is composed of biphasic basaloid cells, the 
cells in center are large polygonal in shape with centrally placed nuclei with 
abundant cytoplasm. 
The tumor cells in the periphery are small round cells with basophilic 
nuclei and scanty cytoplasm exhibiting peripheral palisiding. Basal cell 
adenoma exhibits numerous microscopic patterns like solid, membranous, 
tubular and trabecular based on the arrangement of tumor cells; however the 
most common pattern is solid and mixture of all these patterns28.  
Immunohistochemistry of Basal cell adenoma exhibits luminal and 
abluminal cell differentiation; luminal  cells show positivity for Cytokeratin, 
13 
 
Carcinoembroyonic antigen (CEA), Epithelial membrane antigen (EMA) and 
the abluminal  cells are positive for P63, Calponine, Actin and S10029. 
Differential diagnosis  
Basal cell adenoma should be differentiated from Basal cell 
adenocarcinoma. Basal cell adenocarcinoma shows infiltration of   tumor cells 
into the adjacent tissue. It also shows cellular pleomorphism and high rate of 
cellular proliferation ( >4mitotic figures /10HPF)30. 
Oncocytoma 
Oncocytoma is also called as Oncocytic adenoma and Oxyphil adenoma. 
It is a rare benign tumor of salivary gland composed of oncocytes31. 
Oncocytoma most commonly  seen in elderly individuals and have a 
strong association with radiation exposure32.  Oncocytoma primarily affects the 
major salivary gland especially parotid; less commonly involves minor salivary 
glands. Clinically the tumors are asymptomatic. Grossly the tumors are well 
circumscribed, lobulated masses, rarely exceed 4 cm in diameter, which is  firm 
in consistency. Occasionally some of the tumors undergo cystic degeneration. 
Microscopically the tumors are encapsulated neoplasm, mainly 
composed of oncocytes. Oncocytes are large polygonal cells with eosinophilic 
granular cytoplasm and centrally placed vesicular nuclei and are arranged in 
nested and trabecular pattern with a little fibrovascular stroma. Some of the 
tumors may show cystic and clear cell changes33.  
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Differential diagnosis 
Oncocytoma should be differentiated from other salivary gland tumors 
which undergo oncocytic differentiation like Basal cell adenoma, Pleomorphic 
adenoma, Mucoepidermoid carcinoma, Adenoid cystic carcinoma and 
Epithelial myoepithelial carcinoma34. 
Canalicular adenoma 
Canalicular adenoma is also known as Monomorphic adenoma and 
Basal cell adenoma. Canalicular adenoma occurs in the elderly individuals with 
a mean age of 65 years with female predominance; most commonly affect the 
minor salivary glands with high predilection to the upper lip35.  
Clinically the tumor is small, less than 3cm in diameter, slow growing, 
painless mass, firm in consistency and mobile in nature. 
Grossly the tumor is variably encapsulated, well circumscribed tumor 
mass. The cut surface may be tan to yellow and often shows cystic changes 
filled with gelatinous material. 
Characteristic microscopic feature of Canalicular adenoma is a bilayered 
strands of epithelial cells which runs parallel and at focal places can separate 
and give rise to beaded pattern.  The tumor cells are cuboidal or columnar with 
basophilic nuclei and eosinophilic cytoplasm. Cellular pleomorphism and 
mitosis are rare. The stroma is loosely collagenized with prominent 
vascularity36. 
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Immunohistochemistry 
Canalicular adenoma shows positivity for S100, Cytokeratin, Vimentin 
and Glial fibrillary acid protein37. 
Sebaceous adenoma  
Sebaceous adenoma, one of the rare benign tumors of salivary gland 
accounts for 0.1% of salivary gland neoplasms38. Some of the salivary gland 
tumors like Pleomorphic adenoma, Warthin`s tumor, Mucoepidermoid 
carcinoma, Epithelial myoepithelial carcinoma can also slow sebaceous 
differentiation at focal places which should be differentiated from this entity. 
Sebaceous adenoma most commonly affects the parotid, and is typically 
seen between the age group of 22 to 90 years with slightly male predilection. 
Tumor clinically presents with slow growing painless mass. 
Grossly the tumor is circumscribed and approximately measures 0.4 to 
3cm in diameter. Cut surface of the tumor is solid and cystic which may be 
gray white to yellow in color.  
Microscopically, the tumor is composed of sebaceous cells arranged in 
nests, which are surrounded by fibrous stroma; focal places tumor may show 
squamous differentiation.  
The tumor is strongly positive for CK, Epithelial membrane antigen 
(EMA) and negative for Vimentin, S100, Smooth muscle actin (SMA) the 
myoepithelial markers39. 
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Sebaceous lymphadenoma 
Sebaceous lymphadenoma was first designated by MC Gavran and 
Bauer in the year 196040.The tumor usually presents as slow growing, 
nontender mass, exclusively involving the parotid gland, which commonly 
affects the patient between the age group of 25 to 89 years with no obvious 
gender predilection. 
Grossly it is a encapsulated neoplasm with the size ranging between 1.3 
to 6 cm in diameter; the tumor shows solid and cystic areas which is tan to 
yellow in color, the cystic spaces are usually   filled with sebum. 
Microscopically the tumor is a well circumscribed neoplasm composed 
of uniformly distributed sebaceous cells with cystic and duct like structures, in 
a lymphoid background. The cystic spaces are usually lined by cuboidal, 
columnar, squamous and sebaceous epithelium. Some cases may show 
oncocytic change. 
Occasional tumor may show foreign body giant cell reaction around the 
extravasated sebum; the lymphoid stroma may also show germinal centres41. 
Differential diagnosis of sebaceous lymphadenoma are Low–grade 
mucoepidermoid carcinoma and  Warthin`s tumor. 
Ductal papilloma 
Ductal papilloma arises from excretory ductal unit characterized by 
papillary configuration. These tumors most commonly affect the minor salivary 
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gland and salivary ductal system. Ductal papilloma can be classified into three 
distinct tumor types namely intraductal papilloma, inverted ductal papilloma 
and sialadenoma papilliferum. 
Intraductal papilloma: 
Intraductal papilloma is characterized by proliferation of bland looking 
cuboidal to columnar cells in papillary configuration43. The tumor most 
commonly affect the parotid but  rarely can also involve  the submandibular or 
sublingual glands. 
Intraductal papilloma clinically presents as a submucosal painless mass. 
Most commonly affects the elderly individuals between the age group of  
6th and 7th decade 44. 
Grossly the tumor is unilocular cystic mass approximately measuring 
0.5 to 2  cm in diameter. 
Microscopically the tumor shows cystically dilated structures with 
papillary infolding which are lined by single or double layer of cuboidal or 
columnar cells with a central fibrovascular core. There is no cellular atypia, 
however occasionally tumor shows few mitotic figures. 
The tumor is immunoreactive for Pancytokeratin, Epithelial membrane 
antigen and negative for SMA45.  
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Sialadenoma papilliferum 
Sialadenoma papilliferum exhibits a biphasic growth pattern; the tumor 
exhibits both exophytic squamous pattern and endophytic glandular pattern. 
Sialadenoma papilliferum has similar features of Syringocystadenoma 
papilliferum of the skin42. 
Sialadenoma papilliferum is a rare neoplasm most commonly involving 
the minor salivary gland, mainly the palate. Clinically the tumor presents as a 
painless mass in the surface mucosa. The mean age of presentation is 59 years 
with slightly male predominance44. 
Grossly the tumor is well defined papillary exophytic mass 
approximately measuring 0.3- 2 cm in diameter44 
Microscopically two growth pattern are noted, the exophytic and 
endophytic growth pattern in the oral mucosa. The exophytic component   
exhibits papillary projections which are lined by stratified squamous epithelium 
with a central fibrovascular core. This stratified squamous epithelium may 
show hyperkeratosis, parakeratosis and focal hypergranulosis. 
The endophytic pattern is composed of double layers of outer cuboidal 
and inner columnar cells admixed with few scattered mucous cells. The 
supporting fibrovascular core often  contain few plasma cells and lymphocytic 
infiltrate44. 
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Immunohistochemistry 
Sialadenoma papilliferum is immunoreactive for Cytokeratin, CEA, 
EMA for luminal cells and basal cells show positivity for Vimentin, 
Cytokeratin and Smooth Muscle Actin46. 
Inverted ductal papilloma 
It is a rare type of the ductal papilloma, most frequently arises from 
minor salivary gland with high predilection towards lip and buccal mucosa, 
rarely the tumor may arises from palate and floor of mouth44.  
Inverted ductal papilloma have got a male predilection and affects the 
age group ranging from 28 to 77 years. Clinically inverted ductal papilloma 
presents as a submucosal painless nodular swelling with a central punctum. 
Grossly the tumor is well circumscribed approximately measuring 0.5 to 
1.5 cm in diameter, occasional area showing cystic changes44. 
Microscopically the dilated ductal structure shows papillary infolding 
with fibrovascular core, which is lined by non-keratinized stratified squamous 
epithelium. No cellular atypia and mitotic figures are seen. 
Immunohistochemistry  
The tumor is positive for Pancytokeratin, Epithelial Membrane Antigen, 
CEA and negative for S100, SMA, Vimentin47.  
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Cystadenoma 
It is a rare benign epithelial tumor characterized by proliferation of 
benign ductal epithelial cells resulting in multicystic growth pattern48. 
Previously this entity was considered to be reactive cystic hyperplasia; however 
in recent days it is considered to be a proliferative neoplasm. Cystadenoma 
affects both major and the minor salivary glands of the oral cavity. The mean 
age of presentation is 57 years with a female predominance49. 
Cystadenoma clinically presents as a slow growing, painless, cystic 
mass usually measuring 1cm in diameter which clinically resemble mucocele. 
Grossly it is a well circumscribed tumor mass with or without fibrous 
capsule, cut surface shows multiple cystic cavity or single large cyst. 
Microscopically the tumor shows numerous cystic spaces and these 
cystic spaces are separated by dense fibrous stroma. These cystic spaces are 
lined by cuboidal or columnar epithelium which may be thrown into papillary 
infoldings in some cases where they are called as Papillary cystadenoma. 
Occasionally apocrine, squamous, mucinous and oncocytic differentiation are 
also noted at focal places50. The cystic spaces are filled  with  eosinophilic 
proteinaceous material. Also seen are psammoma bodies and tyrosine rich 
crystals within the secretions. The variants of cystadenoma are Mucinous 
cystadenoma and Oncocytic cystadenoma. 
Differential diagnosis of Cystadenoma is salivary duct cyst, Polycystic 
disease, Low grade mucoepidermoid carcinoma, Papillary variant of acinic cell 
carcinoma and Cystadenocarcinoma51. 
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Mucoepidermoid carcinoma 
Mucoepidermoid carcinoma is a malignant epithelial neoplasm 
composed of proliferation of   mucous secreting cells, intermediate cells and 
epidermoid cells. 
Mucoepidermoid carcinoma is the most common malignant salivary 
gland neoplasm that occurs in adult and in children with the mean age of 
patient presentation being 45 years and a slight higher predilection in female 
population42. One of the important etiological factor is history of exposure to 
radiation and most of the atom bomb survivors of Hiroshima and Nagasaki 
were affected with Mucoepidermoid carcinoma52.Tumor is also frequently 
noted in patients who received radiotherapy for tumors like Leukemia, 
Retinoblastoma and some Brain tumors53. 
Clinically tumor presents as a painless, slow growing tumor mass, which 
is firm in consistency; were as the high grade tumors have rapidly growing 
tendency which is  associated with complains of dysphagia, pain associated 
with facial nerve palsy43.  
Grossly the tumor is partially encapsulated, well circumscribed tumor, 
firm to hard in consistency, occasionally shows cystic spaces filled with 
brownish or mucoid material. High grade tumors may show areas of   
haemorrhage and necrosis43. 
The tumor is composed of three population of cells, the squamous cells, 
intermediate cells and mucous cells which are arranged in nests admixed with 
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haphazardly dispersed mucin filled cystic spaces. The stroma is sclerotic with 
inflammatory cell infiltrate. Occasional cases show extravasation of   mucin49. 
Mucoepidermoid carcinoma can be divided into low grade, intermediate 
grade, high grade. 
Low grade mucoepidermoid carcinoma is mainly composed of 
numerous mucous filled cystic spaces line by mucous cells admixed with solid 
sheets of intermediate cell. 
Some of the cystic cavity may show papillary infoldings, cellular 
pleomorphism and mitotic figures are rare in low grade tumors. Occasional 
tumor may show squamous and clear cell differentiation54. 
Intermediate mucoepidermoid carcinoma is predominantly composed of 
intermediate cells and epidermoid cells, which are usually arranged in sheets 
and nests. The tumor nests are admixed with few scattered cystic spaces which 
are lined by columnar cells and mucous secreting cells. There is moderate 
amount of nuclear pleomorphism and focal areas in tumors may show invasion. 
High grade mucoepidermoid carcinoma predominantly is composed of 
epidermoid cells with few scattered intermediate cells arranged in sheets, nests, 
showing highly pleomorphic cells, with increased mitotic activity. High grade 
tumors exhibit marked infiltration with areas showing necrosis. Perineural and 
lymphovascular invasion is present55. 
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It has been reported that in rare conditions Mucoepidermoid carcinoma 
can arise from Warthin`s tumor and Pleomorphic adenoma56. 
Tumor cells show positivity for Pancytokeratin, variable staining for 
S100, EMA, CEA. P63 may be positive for epidermoid cells, intermediate cells 
and clear cells57. 
Differential diagnosis of   Mucoepidermoid carcinoma is 
Cystadenocarcinoma and Necrotizing Sialometaplasia58. 
Adenoid cystic carcinoma 
Adenoid cystic carcinoma is otherwise called Cylindroma, 
Adenoepithelioma. It is a invasive malignant neoplasm of salivary glands 
composed mainly of epithelial and myoepithelial cells in various 
morphological growth pattern like cribriform, solid, tubular42. 
Clinically the tumor occurs at the peak age group between 5th and 7th 
decade with female predominance59. The tumors most commonly affects the 
major salivary gland like parotid, submandibular gland and rarely sublingual 
gland. Adenoid cystic carcinoma is also reported in other sites like lacrimal 
glands60, esophagus, trachea, bronchus61, uterine cervix, prostate and ovary. 
The tumors are slow growing, infiltrating masses, which are usually 
painful and can induce cranial nerve lesions and facial nerve palsy62. At rare 
instant the tumor may show metastasis as a presenting manifestation63. 
24 
 
Macroscopically the tumors are well circumscribed but rarely 
encapsulated, solid tumor mass, the cut surface of the tumor is grey to tan in 
color. 
Microscopically the tumor cells are arranged in different morphological 
growth patterns like cribriform, tubular, solid, and mixed pattern. The most 
common pattern is cribriform pattern which is composed of numerous 
pseudocystic spaces which are filled with hyalinized eosinophilic material. In 
tubular pattern bilayered epithelium is made up of, the inner ductal epithelial 
cells and the outer myoepithelial cells. Occasional cases show  squamous, 
oncocytic and sebaceous metaplasia64. 
The least common variant is the sloid variant composed of islands of  
basaloid cells admixed with few ductal epithelial cells. The stroma is fibrous. 
Comedo necrosis and perineural invasion is common in Adenoid cystic 
carcinoma. Immunohistochemically, the epithelial cells are strongly positive 
for Cytokeratin, CEA, EMA. The myoepithelial cells are positive for P63, 
Calponine, Actin, S100 protein65. 
Differential diagnosis of Adenoid cystic carcinoma is Polymorphous 
low grade adenocarcinoma, Basaloid squamous cell carcinoma, Epithelial-
myoepithelial carcinoma66 
Acinic cell carcinoma 
It is the malignant epithelial tumor of salivary gland, at focal places 
showing seroacinar cell differentiation42. Acinic cell carcinoma accounts about 
25 
 
3 to 6% of salivary gland neoplasm. Most commonly affect major salivary 
gland, the parotid accounting about 80% to 90%. The tumor is predominantly 
seen in female population with a wide range of age distribution between 30 to 
90 years. 
Clinically patients present with mobile mass, usually painless, slow 
growing; occasionally tumors show nodularity67. Some of the cases may show 
facial nerve involvement68. 
Grossly the tumor is circumscribed, round to oval, lobulated, firm mass 
approximately measuring < 3cm in diameter. The cut surface of the tumor is 
gray white to yellow in color with focal areas showing cystic degeneration69. 
Microscopically Acinic cell carcinoma  exhibit a wide range of cellular 
heterogeneity and morphological diversity which result in numerous 
histological variants of tumors. They also show wide range of varying 
architectural growth patterns and cell types with features of seroacinar 
differentiation69. 
Among this the most common type of cells that we see are acinar cells. 
The acinar cells are round to polygonal in shape, which are uniformly arranged 
with a round, basophilic nuclei, typically located at the periphery and abundant 
pale to basophilic cytoplasm. Acinar cells are composed of zymogen granules,  
which shows positivity for PAS69. 
Intercalated duct cells are cuboidal in shape with centrally located nuclei 
and eosinophilic cytoplasm which line the duct like structure. The non specific 
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glandular cells are polygonal in shape with a large, vesicular nuclei and 
amphophilic cytoplasm. 
Acinic cells exhibit a variety of growth patterns - microcystic, solid, 
follicular and papillary pattern. The microcystic pattern is the most common 
pattern which is also called as lattice like pattern because of the presence of 
numerous cystic spaces within the tumor. In this type the acinar cells are 
admixed with vacuolated cells and intercalated ductal cells69. 
Occasionally the tumors shows intracystic papillary proliferation, and 
hobnailing pattern. One of the rare variant is the follicular variant composed of 
multiple cystic spaces lined predominantly by intercalated ductal cells. The 
cystic spaces contain homogenous proteinaceous material70.  
The stroma is made up of delicate fibrovascular tissue. Occasionally 
tumors show psammoma bodies and lymphocytic infiltrate with germinal 
centre formation. 
Acinic cell carcinoma are immunoreactive for Cytokeratin, 
Carcinoembryonic antigen and COX-2 71. 
Differential diagnosis of Acinic cell carcinoma is Papillary 
cystadenocarcinoma of salivary gland, Mucoepidermoid carcinoma and 
Metastatic granular renal cell carcinoma. 
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Polymorphous low grade adenocarcinoma 
Polymorphous low grade adenocarcinoma (PLGAC) is the second most 
common malignant neoplasm of minor salivary gland72.  
The tumor is characterized by diverse morphological features, uniform 
cellular features with an infiltrating growth pattern and a low metastatic 
tendency. 
The tumors usually occur with the mean age of 59 years with female 
predominance. These tumors also show ethnic predilection towards black 
population43. 
Polymorphous low grade adenocarcinoma is a slow growing, painless 
mass, most commonly involve the palate, cheek and upper lip. Some of the 
tumors show ulceration of the surface73. Occasional cases of Polymorphous low 
grade adenocarcinoma may be associated with Carcinoma ex-pleomorphic 
adenoma74. 
Grossly the tumor is well circumscribed, approximately measuring 0.4 
to 6cm in diameter which is tan to gray in color with an infiltrating margin. 
Microscopically the tumor cells exhibit variable growth patterns like 
solid, tubular, fascicular, cribriform and papillary growth pattern.  The tumor 
cells are uniform which are small to medium in size with a round to oval 
nuclei, dispersed fine chromatin, inconspicuous nucleoli and abundant 
eosinophilic cytoplasm. 
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The stroma is hyalinized or mucoid. Some of the tumors show 
psammoma bodies and tyrosine rich crystalloids75. 
The tumor cells are immunoreactive for Cytokeratin, Epithelial 
membrane antigen, S100and Vimentin76.The proliferative activity of the tumor 
cells can be identified using Ki67, which is usually low for Polymorphous low 
grade adenocarcinoma. 
Differential diagnosis: 
Differential diagnosis of Polymorphous low grade adenocarcinoma is 
Pleomorphic adenoma and Adenoid cystic carcinoma77. 
 Epithelial – Myoepithelial carcinoma 
Epithelial-myoepithelial carcinoma can also be called as Glycogen rich 
adenocarcinoma, Clear cell adenoma or Tubular carcinoma78.  
It is a rare malignant neoplasm usually forms duct like structure lined by 
double layered epithelium; the inner ductal epithelium and the outer 
myoepithelium. The tumor most commonly seen with the mean age of 60 years 
with female predominance 79. 
The tumor most commonly affect the parotid in 75% of cases, and 
submandibular gland in 10-12% of cases. Clinically the tumors present as a 
slow growing, painless mass rarely present with facial nerve palsy80. 
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Grossly the tumor is well defined, nodular, multilobular swelling 
measuring 2 to 8 cm in diameter, which is firm in consistency. The cut surface 
of the tumor is gray white to yellow in color with cystic areas 81. 
Microscopically the tumor is composed of epithelial and myoepithelial 
cells which form double layered ductal structures, which contains 
proteinaceous material. 
The luminal cells are cuboidal to columnar with centrally located round 
to oval nuclei and eosinophilic cytoplasm. 
The abluminal cells are large, polygonal, spindle in shape with vesicular, 
eccentrically placed nuclei with clear cytoplasm, which are located at the 
periphery surrounding the luminal cells. Some of the tumor cells are arranged 
in sheets and nesting pattern. Often the stroma is fibrous surrounding the tumor 
cells. The stroma may also be Myxoid and hyalinized. 
Some of the tumor cells show sebaceous differentiation and oncocytic 
differentiation82. Cellular atypia is minimal, mitotic figures are usually rare 2-
3/10HPF. Minority of the tumor cells may show infiltrative growth pattern and 
perineural invasion83. 
Immunohistochemistry  
Epithelial- myoepithelial carcinoma composed of ductal cells and 
myoepithelial cells. The ductal cells are strongly positive for Cytokeratin and 
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CAM5.2.The Myoepithelial cells are positive for P63, S100, Vimentin, 
Calponine, Glial Fibrillary Acidic Protein. 
Differential diagnosis of Epithelial-myoepithelial carcinoma is 
Pleomorphic adenoma, Myoepithelial carcinoma, Adenoid cystic carcinoma, 
Polymorphous low grade adenocarcinoma. 
Clear cell carcinoma (NOS) 
Clear cell carcinoma is otherwise called as Adenocarcinoma of clear 
cell. The tumor is mainly composed of monomorphic population of epithelial 
cells which exhibit clear cytoplasm. 
Clear cell carcinoma is diagnosed when other tumors like Myoepithelial 
carcinoma, Clear cell oncocytoma and Mucoepidermoid carcinoma exhibiting 
clear cell feature are excluded84. 
Clear cell carcinoma is a uncommon salivary gland neoplasm, most 
commonly involve the minor salivary glands of oral cavity. It most commonly 
occurs  between  4th and  7th decade, there is no sex predilection. The tumor 
clinically presents as a slow growing, painless mass with focal areas showing 
ulceration85. 
Grossly the tumor is unencapsulated and poorly circumscribed 
approximately measuring 3 cm in diameter; the cut surface of the tumor is grey 
white in color and firm in consistency. 
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Microscopically, the tumor cells are arranged in solid sheets, trabecular 
and nests; the individual cells are round to polygonal in shape with 
eccentrically located round nuclei showing granular cytoplasm, inconspicuous 
nucleoli with abundant clear cytoplasm which is usually positive for PAS. 
Mitosis is uncommon. A small subset of tumor population may show 
eosinophilic cytoplasm86. 
Clear cell carcinoma shows variable immunoreactivity for Low 
molecular weight Cytokeratin  and  negativity for S100, Calponine and Actin . 
Basal cell adenocarcinoma  
Basal cell adenocarcinoma synonymously called as Hybrid basal cell 
adenocarcinoma87.Basal cell adenocarcinoma has got a similar morphological 
findings of basal cell adenoma; but it is highly invasive tumor with potent 
metastatic potential88. 
Majority of the Basal cell adenocarcinomas arise denovo but some cases 
arise from preexisting Basal cell adenoma89.  Basal cell adenocarcinoma is a 
rare salivary gland tumor most commonly affects the major salivary glands, the 
parotid and submandibular gland90. There is no gender predilection; peak 
incidence ranges between 6th and 7th decade. 
Tumor clinically presents as long standing painless mass. Occasional 
cases may present  as painful mass. 
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Basal cell adenocarcinoma ranges between the size of 2 to 3.5 cm in 
diameter; it is usually a unencapsulated tumor mass with focal areas showing 
invasion to the adjacent tissue . 
Microscopically, the tumor cells are arranged in solid sheets, trabecular, 
tubular, membranous patterns with peripheral palisading of the tumor nests. 
Basal cell carcinoma exhibits two distinct   population of cells, the dark 
basaloid cells and large pale cells. 
The basaloid cells are usually arranged in solid and membranous pattern. 
The large pale cells are usually arranged in ductal structure. The tumor cells 
exhibit mild nuclear pleomorphism which is virtually indistinguishable from 
basal cell adenoma. The tumor shows extensive areas of necrosis. Mitosis is 
usually 4/10 HPF. The tumor commonly shows extensive vascular invasion. 
Immunohistochemistry  
Basal cell adenocarcinoma is composed of both ductal and myoepithelial 
cells. The ductal cells are positive for Cytokeratin, focal positivity is noted in 
Epithelial Membrane Antigen, CEA. The myoepithelial cells are positive for 
SMA, S100, Vimentin. KI-67 index is higher in Basal cell adenocarcinoma 
than in Basal cell adenoma91. 
Differential diagnosis 
Basal cell adenocarcinoma should be differentiated from basal cell 
adenoma, Adenoid cystic carcinoma, Small cell carcinoma,  Large cell 
Neuroendocrine carcinoma90. 
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Sebaceous carcinoma 
Sebaceous carcinoma is synonymous with Sebaceous adenocarcinoma. 
Sebaceous carcinoma is a malignant epithelial tumor composed of sebaceous 
cells with varying degree of nuclear pleomorphism and invasion92. 
Sebaceous carcinoma is a rare tumor of salivary gland most commonly 
affecting the major salivary glands usually the parotid, sublingual and 
submandibular gland93. 
Sebaceous carcinoma usually presents with bimodal age distribution, the 
peak incidence is seen in third and seventh decade. 
Tumor typically present as slow growing tumor mass associated with 
pain and often shows facial nerve involvement94. 
Grossly the tumor ranges from 0.5 to 8.5 cm in diameter, which is 
usually well circumscribed; cut surface of the tumor is gray white in color. 
Microscopically the tumor cells are arranged in sheets and nests with 
variable degree of nuclear pleomorphism. The tumor may also exhibit 
numerous duct like structures admixed with cystic spaces. The tumor cells may 
also exhibit squamous and basaloid differentiation. 
Sebaceous lymphadenocarcinoma 
Sebaceous lymphadenocarcinoma is a rare malignant salivary gland 
neoplasm which is the counter part of benign tumor Sebaceous lymphadenoma. 
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The tumor presents between the age group of 50 to 70 years with male 
predominance.  
Clinically the tumor presents as a painless tumor mass. 
Grossly the tumor is well circumscribed which is yellow to gray in color 
with focal areas showing tumor infiltration94. 
Microscopically, the tumor   shows characteristic feature of   sebaceous 
adenoma intermingled with carcinomatous component showing cellular 
pleomorphism with increased mitotic activity94.The tumor may arise from 
lymphadenoma as well. The tumor may also show xanthogranulomatous  
inflammation. 
Cystadenocarcinoma  
Cystadenocarcinoma is the malignant counterpart of   benign tumor  
cystadenoma. It is a rare low grade invasive salivary gland neoplasm 
characterized by numerous cystic spaces with papillary projections, so it is also 
called as papillary cyst adenocarcinoma95. The tumor is also called as 
malignant papillary cystadenoma, and Low grade papillary adenocarcinoma96. 
About 65% of tumors affect the major salivary glands most commonly the 
Parotid.  
The remaining 35% of tumors affect the minor salivary gland. About 
70% of   tumors are seen with the mean age of over 50 years, there is no sex 
predilection97. 
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Clinically the tumor presents as a slow growing tumor mass; occasional 
cases may show tumor infiltrate into nasal cavity or in maxillary sinuses.  
Grossly the tumors are partially circumscribed with the average size of 
2.2 to 2.4 cm in diameter. Cut surface of the tumors reveal multiple cystic 
spaces filled with brownish to mucoid material. 
Microscopically cystadenocarcinoma resembles the benign tumor 
cystadenoma, however cystadenocarcinoma shows infiltration  into the 
surrounding tissue. 
Cystadenocarcinoma shows multiple cystic spaces lined by the cuboidal 
Or columnar cells with mild to moderate nuclear pleomorphism with very few 
mitotic figures97. 
About 75%  of  tumor shows papillary growth pattern called as papillary 
cystadenocarcinoma. Some of the tumors may show marked nuclear 
pleomorphism  with prominent nucleoli98. 
Cystadenocarcinoma is usually immunoreactive for Pancytokeratin, 
EMA and Carcinoembryonic Antigen99. 
Differential diagnosis: 
Papillary Cystadenocarcinoma should be differentiated from, 
Cystadenoma, Low-grade Mucoepidermoid carcinoma, Polymorphous low 
grade carcinoma, Papillary variant of Acinic cell carcinoma, Salivary duct 
carcinoma, Metastatic papillary thyroid carcinoma. 
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Low grade cribriform cystadenocarcinoma 
Low grade cribriform cystadenocarcinoma is a variant of   
Cystadenocarcinoma which was categorized in 2005 WHO classification. It is a 
rare malignant salivary gland neoplasm100. Most commonly affects the parotid 
gland, occasionally involve the submandibular and  minor salivary gland. Most 
of the patients are in 6th and 7th decade  with female predominance100. 
Low grade cribriform cystadenocarcinoma is a well circumscribed 
neoplasm without a capsule. The tumor is mainly composed of multiple 
cystically dilated duct like spaces. The spaces are lined by cells which are 
usually multilayered and form micropapillary projections, tufting and 
cribriform pattern101. 
These proliferating ductal cells are usually cuboidal and polygonal cells 
with dispersed chromatin and a small nucleoli. 
Cellular pleomorphism is usually absent with very minimal mitotic 
figures and absence of necrosis. Some of the tumors may show microinvasion. 
No perineural or vascular invasion noted102. 
Mucinous Adenocarcinoma 
Mucinous adenocarcinoma is otherwise called colloid carcinoma. It is a 
malignant epithelial tumor characterized by clusters of malignant epithelial 
cells floating in a pool of mucin. 
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Mucinous carcinoma present between the age group of 42 to 86 years 
with no obvious sex predilection. Tumors most commonly affect the minor 
salivary glands particularly the palate and can also affect submandibular and 
sublingual glands103 The tumor clinically presents as a slow growing tumor 
mass, occasional cases may show ulceration. 
Grossly the tumor measures 2 to 7 cm in diameter. External surface of 
the tumor is bosselated; cut surface of the tumor is grey white in color with 
multiple cystic spaces filled with gelatinous mucinous material. 
Microscopically the tumor cells are arranged in solid nest and duct like 
structure in variable size. These clusters of tumor cells float in the pool of 
mucin which is separated by fibrous septa. The epithelial cells may be cuboidal 
or columnar with centrally placed hyperchromatic nuclei in a clear cytoplasm, 
infrequent mitosis are also noted. 
Immunohistochemistry: 
Mucinous adenocarcinoma is strongly positive for Pancytokeratin. 
Tumor usually negative for Smooth Muscle Actin, Estrogen and  
Progesterone104. 
Oncocytic carcinoma 
Oncocytic  carcinoma it is a rare malignant neoplasm characterized by 
proliferation of oncocytes with an infiltrative nature. These tumors are also 
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called as Oncocytic adenocarcinoma, Malignant oncocytoma,  Malignant 
oxyphilic adenoma . 
These tumors usually arises denovo and also arises from the persisting 
oncocytoma.The tumor  most commonly is seen in elderly individuals, with a 
mean age of  about 60 years with a male predominance43. 
Parotid is the most commonly affected organ in 80% of cases and also 
seen in submandibular gland, intraoral and upper respiratory tract. 
Patient  complaints as a slow growing painless mass. But some rare 
cases present with complaints of painful mass with facial nerve palsy.  
Grossly Oncocytic carcinoma is a variably capsulated tumor mass, may 
be single or multifocal. Cut surface is grey brown to tan, firm in consistency 
with focal areas may show necrosis. 
Microscopically the tumor cells are arranged in sheets, nests and 
occasionally show ductal differentiation. The individual tumor cells are round 
to polygonal in shape with  a centrally placed vesicular nuclei in a granular 
eosinophilic cytoplasm. The tumor also shows frequent mitotic figures with 
focal areas showing necrosis. There is also evidence of perivascular and 
neuronal infiltration. 
Ki67 index is useful in differentiating oncocytoma from oncocytic 
carcinoma which have a high proliferative index105. 
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Salivary duct carcinoma 
Salivary duct carcinoma is a aggressive adenocarcinoma which have a 
similar features of ductal carcinoma of breast 106.Salivary duct carcinoma 
accounts approximately about 2% of all salivary gland neoplasms106.The peak 
incidence is seen between the age group of 6th to 7th decade  with male 
predominance.  
The tumor most commonly affects the parotid gland but is also noted in 
submandibular and minor salivary gland. Salivary duct carcinoma arises 
denovo or develops as a malignant component of  Carcinoma ex pleomorphic 
adenoma107. 
The tumor clinically presents as a rapid growing painful mass, 
associated with facial nerve palsy. 
Grossly the tumor is unencapsulated, solid mass, approximately 
measuring 6cm in diameter. Cut surface of the tumor is solid with focal areas 
showing necrosis and cystic changes43. 
Microscopically there is a mixture of two different components, the 
intraductal and invasion component. In intraductal component there are large, 
multiple dilated ductal structures showing papillary, cribriform or solid 
architecture with central area often showing comedo necrosis. Focal areas of 
tumor also show psammoma bodies and squamous differentiation with   
keratinization. 
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In invasive component, the tumor cells are arranged in cords and 
irregular glands with a desmoplastic stroma. The individual cells are large with 
highly pleomorphic large nuclei with coarse chromatic and a prominent 
nucleoli in an abundant eosinophilic cytoplasm. 
There is increased mitotic activity along with apocrine metaplasia. The 
tumor also shows lymphovascular   invasion. 
The tumor cells show strongly immunoreactivity for Her2neu, 
Cytokeratin, EMA and CEA108. 
Differential diagnosis of salivary duct carcinoma is Adenocarcinoma 
(NOS), Metastatic adenocarcinoma and   Squamous cell carcinoma43. 
Adenocarcinoma (NOS) 
Adenocarcinoma is a malignant salivary gland tumor which shows 
ductal differentiation but lacking glandular diagnostic features of other defined 
tumors categoriesed42. 
The tumor is most commonly seen in elderly individuals between sixth 
and seventh decade with female predominance. Parotid is most commonly 
affected major salivary gland. Patient clinically presents with a painless solitary 
mass and some of the tumors are fixed to the underlying soft tissue109. 
Grossly the tumors show infiltrating borders and focally circumscribed 
tumor mass. Cut surface of the tumor is gray white in color, firm in consistency 
with areas of necrosis and haemorrhage. 
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Microscopically the tumors are characterized by variable glandular or 
ductal structures with variable growth pattern; Some of the architectural 
patterns are solid, papillary, sheets, trabecular, cords and cribriform pattern, 
lacking the characteristic histological features of recognized salivary gland 
neoplasms. 
Small foci of tumors may show features of Adenoid cystic carcinoma, 
Epithelial- myoepithelial carcinoma and Cystadenocarcinoma. 
The tumors show invasion into the adjacent salivary gland parenchyma, 
with areas of necrosis, perineural and vascular invasion. Adenocarcinoma 
(NOS) can be graded into low grade, intermediate grade, high grade based on 
the gland formation, cellular atypia, mitotic index and necrosis. 
Low grade tumors are distinguished from high grade based on the 
increased nuclear pleomorphism, high mitotic figures, extensive areas of 
necrosis and perineural and lymphovascular invasion110. 
Immunohistochemistry: 
The tumor cells are usually positive for Pancytokeratin, Negative for 
S100, SMA and Calponine69. 
Differential diagnosis: 
  Adenocarcinoma (NOS) is based on exclusion of other gland forming 
carcinomas of salivary gland. The differential diagnosis are Polymorphous low 
grade adenocarcinoma, Epithelial-myoepithelial carcinoma, Salivary duct 
carcinoma, Cystadenocarcinoma   and Metastatic adenocarcinoma69. 
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Myoepithelial carcinoma 
Myoepithelial carcinoma is a rare malignant neoplasm of salivary gland, 
which is the malignant counterpart of Myoepithelioma and it accounts about < 
0.4% of salivary gland tumors111. 
Myoepithelial carcinoma is composed of tumor cells showing 
myoepithelial differentiation with cellular pleomorphism, infiltrative growth 
pattern and metastatic potential112. 
The mean age of presentation is 55 years, there is no gender 
predilection. Tumor predominantly involves parotid gland in 75% of cases and 
also involves minor salivary gland preferentially in palate, 25%112. 
Myoepithelial carcinoma usually arises from the preexisting benign 
lesion like Myoepithelioma, Pleomorphic adenoma but can also arises denovo. 
Grossly it is a unencapsulated solid, nodular tumor mass. Cut surface of 
the tumor is grey white to tan in color. Focal area showing cystic degeneration 
filled with gelatinous material113. 
Microscopically, the tumor cells are arranged in various morphological 
patterns like reticular, trabecular, sheet-like and lace–like growth patterns, 
similar to Myoepithelioma. Myoepithelial carcinoma also shows numerous cell 
types consisting of spindle, epithelioid, plasmacytoid and clear cell type. The 
stroma is hyalinized or Myxoid .The tumor often undergoes myxoid 
degeneration. 
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Immunohistochemistry  
Myoepithelial carcinomas are usually immunoreactive for P63, CK14, 
S100. Differential diagnosis of Myoepithelial carcinoma is Myoepithelioma. It 
can be differentiated based on the pleomorphism of the cells, increased mitotic 
activity and perineural invasion. 
Carcinoma ex pleomorphic adenoma 
Carcinoma ex pleomorphic adenoma is a malignant epithelial tumor 
usually arising from a benign mixed tumor or recurrent  pleomorphic adenoma. 
The incidence of carcinoma ex pleomorphic adenoma ranges from 0.9 to 14% 
of salivary gland neoplasm81. 
Parotid gland is most commonly affected in 82 % of cases, but tumor 
may also occur in other regions like submandibular and sublingual glands114.  
Most commonly affected age group is between 6th to 7th decade. Patient 
clinically presents as rapidly growing painless tumor mass; but in rare cases the 
tumor is painful, fixed, ulcerated and associated with facial nerve palsy. 
Recurrence and metastasis is commonly noted114. 
Grossly the tumor is poorly circumscribed with intensive infiltration to 
the surrounding tissue; approximately the size ranges from 1.5 to 25cm in 
greatest diameter; cut surface of the tumor may show areas of necrosis, 
hemorrhage and cystic regeneration115.  
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Microscopic finding of carcinoma ex pleomorphic adenoma requires 
presence of both benign mixed tumor and malignant carcinomatous component. 
The tumor usually shows infiltrative growth pattern with high nuclear 
pleomorphism, increased mitotic figures and extensive areas of tumor   
necrosis. 
The malignant component is dominated most frequently by Poorly 
differentiated adenocarcinoma (NOS) or salivary duct carcinoma. But 
occasionally Polymorphous low grade adenocarcinoma, Mucoepidermoid 
carcinoma, Adenoid cystic carcinoma or  Myoepithelial  carcinoma may be 
noted as a malignant component116. 
Differential diagnosis of Carcinoma ex pleomorphic adenoma is 
Salivary  duct carcinoma and Carcinosarcoma.             
Carcinosarcoma   
Carcinosarcoma is a malignant mixed tumor composed of both 
carcinomatous and sarcomatous component42. The tumor is also called as 
malignant mixed tumor which accounts for <0.2% of malignant tumors of 
salivary gland. 
The tumor most commonly involve parotid, submandibular and palate. 
The mean age of presentation is 58years.The tumor most commonly arises 
denovo but in some cases the tumor may arise from recurrent pleomorphic 
adenoma117. 
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Carcinosarcoma clinically presents as a painful mass, usually fixed to 
the underlying tissue with areas of ulceration. Some of the tumors may show 
facial nerve palsy and   regional lymphnode involvement. 
Microscopically Carcinosarcoma is a biphasic tumor composed of both 
carcinomatous and sarcomatous components. Most of the tumors exhibit 
prominent sarcomatous element mainly the chondrosarcoma, osteosarcoma, 
fibrosarcoma. The most common carcinomatous component are 
undifferentiated carcinoma and  Poorly differentiated adenocarcinoma. 
Occasionally tumors shows carcinomatous element such as Salivary 
duct carcinoma and Adenoid cystic carcinoma118. 
Metastasizing pleomorphic adenoma 
Metastasizing pleomorphic adenoma is a rare salivary gland tumor 
which is also called as Malignant mixed tumor. The tumors are histologically 
benign looking Pleomorphic adenoma which manifest with local or distant 
metastasis 42. 
The mean age of presentation of tumors are 33 years with no obvious 
sex predilection. Most of the tumors are seen in parotid but some tumors are 
also distributed in submandibular gland and palate119. 
The tumors usually arise from the background of longstanding 
Pleomorphic adenoma or multiple recurrent pleomorphic adenoma. The mean 
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age of development of metastasizing pleomorphic adenoma from a recurrent or 
longstanding pleomorphic adenoma is 16 years120 
Microscopically the tumors are similar to benign pleomorphic adenoma 
with local or distant metastatic potential. Some of the tumors shows nuclear 
pleomorphism and mitotic figures.  Although there is no evidence of frank  
malignancy. 
Immunohistochemistry:  
Immunohistochemistry which is similar to conventional pleomorphic 
adenoma; the luminal cells are positive for CK3, CK6, CK10 and CK13.  The 
myoepithelial cells are positive for P63, Cytokeratin, S100, Vimentin and 
SMA.  
Squamous cell carcinoma 
Squamous cell carcinoma is a primary malignant epithelial tumor, which 
is mostly  confined to major salivary gland parotid.  
The tumors are   mainly composed of epidermoid cells which produces 
keratin. In addition, it is essential to exclude the tumors that can metastases 
from overlying skin, external auditory meatus and  upper digestive tract. 
Primary Squamous cell carcinoma of the major salivary glands are rare. 
The tumors which accounts less than 1% of salivary gland tumors.  
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The tumors most commonly seen with the mean age group of 60 to 65 
years with male predominance. Some of the tumors are strongly associated 
with previous radiation exposure for long period of time121. 
Patient clinically presents as a painless, rapidly enlarging tumor mass. 
Some tumors are painful, fixed to the underlying tissue associated with facial 
nerve palsy. 
 Grossly the tumor is large, firm mass with evidence of infiltration to the 
adjacent tissue. The cut surface of the tumor is gray white with areas of 
necrosis. 
Microscopically the tumor is similar to that of Squamous cell carcinoma 
of the head and neck, which can be classified into well differentiated, 
moderately differentiated and poorly differentiated tumors43. Some tumors may 
show ductal dysplasia and squamous metaplasia. The tumors usually show 
perineural and local invasion. 
Differential diagnosis  
The tumor should be differentiated from Metastatic Squamous cell 
carcinoma, Mucoepidermoid carcinoma, Salivary duct carcinoma. 
Small cell carcinoma 
Small cell carcinomas are extremely rare malignant epithelial tumors 
showing small cells with scanty cytoplasm, fine nuclear chromatin and 
inconspicuous nucleoli. 
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Most of the small cell carcinomas exhibit neuroendocrine 
differentiation. The tumors are more commonly seen in male population in 5th 
and 7th decade122. The tumors most commonly affect the parotid and rarely 
involve the submandibular and minor salivary gland. 
Clinically, the tumors present as painless rapidly growing masses, with 
cervical lymphadenopathy and facial nerve palsy123. 
Grossly the tumors are firm, grey white in color, poorly circumscribed 
tumor masses often infiltrative into the adjacent tissue. The tumors are 
commonly accompanied with necrosis and haemorrhage. 
Microscopically small cell carcinomas are characterized by sheets, 
cords, nests of anaplastic small sized tumor cells in a variable amount of 
fibrous stroma. 
Regardless of cellular size, nuclear chromatin is finely granular with 
inconspicuous nucleoli. Cell borders are ill defined with nuclear molding. 
Numerous mitotic figures are present with extensive areas showing necrosis, 
vascular and perineural invasion. 
Immunohistochemistry 
Most of the small cell carcinomas are positive for Neuron Specific 
Enolase (NSE), Chromogranin, Synaptophysin, Neurofilament and about three 
fourth of the tumors are immunoreactive for Cytokeratin 20. 
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Large cell carcinoma 
Large cell carcinomas are high grade malignant salivary gland tumors 
composed of large Pleomorphic cells with abundant cytoplasm42. 
Absence of component of any other specific tumor type should be 
confirmed before making the diagnosis of salivary gland large cell carcinoma. 
Rarely these tumors exhibit neuroendocrine differentiation called Large cell 
neuroendocrine  carcinoma124 . 
The tumors   are most commonly seen in elderly individuals with mean 
age of 60 years. No obvious sex predilection is noted. The tumors most 
commonly involve the parotid;  the tumor clinically presents as a rapidly 
growing fixed mass which is firm in consistency. Commonly associated with 
facial nerve palsy and cervical lymphnode involvement. 
Grossly the tumor is poorly circumscribed, solid tumor which is tan to 
white in color. Focal areas may show  necrosis and haemorrhage. 
Microscopically the tumor cells are arranged in sheets and trabecular 
pattern which are composed of large Pleomorphic cells with abundant 
eosinophilic cytoplasm. The nuclei are polygonal in shape with prominent 
nucleoli and coarse chromatin. The cells are bizarre with well defined cell 
borders. The stroma is fibrous69. Mitotic figures are frequent with prominent 
perineural and vascular invasion. 
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Immunohistochemistry   
 Large cell carcinoma are positive for Cytokeratin and EMA Large cell 
neuroendocrine carcinoma are positive for Chromogranin, Synaptophysin, 
Neuron – Specific Enclose (NSE) 
Differential diagnosis  
Large cell carcinoma should be differentiated from Metastatic malignant 
melanoma, Anaplastic large cell lymphoma, Metastatic undifferentiated 
carcinoma125. 
Lymphoepithelial carcinoma  
Lymphoepithelial carcinoma is also called as undifferentiated carcinoma 
having lymphoid stroma126.Lymphoepithelial carcinoma shows histological 
features identical to that of nasopharyngeal origin. 
Most of the lymphoepithelial carcinomas arise denovo or from 
preexisting lymphoepithelial sialadenitis. Lymphoepithelial carcinomas are rare 
malignant salivary gland tumors although higher incidence have been reported 
in Mangolians127 and South Chinese population. It is most commonly seen with 
the mean age of 40 years and has  slight female predominance. 
The tumor most commonly involves the parotid in 90% of cases, 
followed by submandibular, sublingual and minor salivary gland. The tumor 
clinically presents as a rapidly growing firm mass with facial nerve palsy. 
About 40% of patients also show cervical lymphadenopathy128. 
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Grossly the tumors are solid to firm, ranging from 1 cm to 10 cm in 
diameter. The cut surface of the tumor is well circumscribed, partially 
encapsulated and typically shows extensive infiltration into the adjacent tissue. 
Microscopically the lymphoepithelial carcinoma is characterized by 
cluster formation of large anaplastic cells enclosing within a prominent sheet of 
lymphoid cells. Most of the tumor cells often show infiltration into the adjacent 
salivary gland in lymphoid stroma. 
The tumor cells are usually arranged in solid sheets and in trabecular 
pattern. The tumor cells are large polygonal in shape with vesicular nuclei and 
a prominent eosinophilic  nucleoli  with an abundant amphophilic cytoplasm. 
There is increased mitotic activity and  perineural invasion is common. 
The tumor cells are positive for Pancytokeratin, EMA and negative for 
lymphoid markers129. P63 shows diffuse positivity and Ki67 labeling  
index is high. 
Differential diagnosis  
Metastatic lymphoepithelial carcinoma, Large cell carcinoma, Malignant 
lymphoma and Lymphadenoma. 
Sialoblastoma 
Sialoblastoma is a rare aggressive malignant salivary gland tumor 
usually present at birth42 .Sialoblastoma is also called as congenital basal cell 
adenoma, basaloid adenoma and embryoma.  
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Sialoblastoma most commonly affects the parotid gland and 
submandibular gland. Most of the tumors are seen within the first decade of 
life, occasional cases seen in second and third decade of life 130.   
Clinically the tumor presents as a painless, firm mass with focal areas 
showing ulceration and facial nerve palsy. Occasional cases may show 
coexistence with congenital nevi. 
Macroscopically the tumor is partially encapsulated, firm mass ranging 
from 1.5 to 15 cm in diameter, focal areas in the tumor may show infiltration. 
Cut surface of the tumor is tan to yellow in color with areas of haemorrhage  
and necrosis. 
Microscopically the tumor is mainly composed of basaloid cells. The 
individual cells are round to oval nuclei with inconspicuous nucleoli and a 
scanty eosinophilic cytoplasm.  
The cells exhibit variable pleomorphism. The tumor cells are usually 
arranged in solid sheets, nest and the outer layer shows nuclear palisading. 
Some of the myoepithelial cells in the tumors may show sebaceous and 
squamous differentiation131.The stroma is variable and consists of myxoid 
tissue, fibrous, cellular fibroblastic areas. 
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Immunohistochemistry 
The tumor cells are usually positive for Pancytokeratin like CK5, CK6, 
CK7, CK14 and negative for CK20132. Myoepithelial cells are positive for 
SMA, S100 and Calponine. 
Differential diagnosis  
Sialoblastoma should be distinguished from Basaloid neoplasms like 
Basal cell adenoma, Basal cell adenocarcinoma and Adenoid cystic carcinoma. 
Immunohistochemistry 
Most of the salivary gland neoplasms arise from or differentiate towards 
the same cell lineage like epithelial (ductal and acinar), myoepithelial and basal 
cell. Similarly each cell can also undergo different metaplastic change which 
results in overlap at all levels133. 
Salivary gland tumors often show a variety of growth patterns and 
significant morphological variability which results in the diagnostic difficulties 
of salivary gland tumors134. Although Haematoxylin & Eosin (H&E)  
staining is the gold standard for diagnosis of salivary gland tumors, 
immunohistochemistry enhances the accuracy and serves as a helpful tool in 
cases to  investigate the subjects that cannot be assessed by histological 
examination like nature of cell, differentiation status, cell proliferation and 
tumor protein expression. 
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Cell differentiation: 
Salivary glands are composed of four types of cells, ductal, acinar, 
myoepithelial and basal cells. The ductal and acinar cells are called luminal 
cells; myoepithelial and basal  cells are called abluminal cells. All these four 
cells are usually positive for Pancytokeratin. In addition ductal and acinar cells 
show positivity for EMA and CEA.  The acinar cells also show α- amylase 
positivity. The myoepithelial cells are positive for CK14, P63, Muscle Specific 
Actin (MSA), Calponine, Podoplanin135, Vimentin.  S100 protein staining is 
variable for all four cells in the salivary gland. 
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Summary of the useful Immunohistochemical markers of salivary 
gland tumors in general surgical pathology practice136 
  
Markers 
Positivity in  cells of 
normal salivary gland 
Uses and significance for 
salivary gland tumors 
Pan-cytokeratin (CK) 
[AE1/AE3] 
Both luminal and 
abluminal cells 
Epithelial marker; differential 
diagnosis between 
myoepithelioma/ myoepithelial 
carcinoma or “undifferentiated 
carcinoma” and non-epithelial 
tumors 
Epithelial membrane 
antigen (EMA) 
Luminal cells 
Ductal (luminal) cell marker; 
apical staining pattern; bubbly 
positive in sebaceous cells 
Carcinoembryonic 
antigen (CEA)  
Luminal cells Ductal (luminal) cell marker 
α-Smooth muscle 
actin (SMA) 
 
Myoepithelial cells 
Myoepithelial marker (high 
specificity, very useful) 
Calponine Myoepithelial cells 
Myoepithelial marker (high 
specificity, very useful) 
Muscle-specific actin 
(MSA) 
Myoepithelial cells 
Myoepithelial marker (high 
specificity) 
p63 
Myoepithelial and basal 
cells 
Myoepithelial marker (note: also 
positive for basal and 
squamous epithelial cells) 
 
CK14 
Myoepithelial and basal 
cells 
Myoepithelial marker (note: also 
positive for basal and 
squamous epithelial cells) 
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Glial fibrillary acidic 
protein (GFAP) 
Myoepithelial cells 
(variable) 
Myoepithelial marker (low 
sensitivity); highly positive in 
pleomorphic adenoma and 
myoepithelioma 
S-100 protein 
 
Variable 
Myoepithelial marker (good  
for screening, low specificity) 
Vimentin 
 
 
Myoepithelial cells 
Myoepithelial marker (good for 
screening, low specificity 
Ki-67 [MIB-1] Few cells 
Cell proliferation marker; 
differential diagnosis between 
benign and malignant tumors; 
prognostic factor 
P53 Negative  
Differential diagnosis between 
benign and malignant 
tumors; prognostic factor 
HER2/neu 
Negative to weakly 
positive in 
ductal cells 
Highly over expressed in salivary 
duct carcinoma; diagnosis 
of non-invasive carcinoma ex 
pleomorphic adenoma; 
expected use for molecular 
targeted therapy 
α-Amylase Acinar cells 
Positive in Acinic cell carcinoma 
(low sensitivity) 
Androgen receptor 
(AR) 
Negative 
Often positive in salivary duct 
carcinoma; diagnosis of 
non-invasive carcinoma ex 
pleomorphic adenoma; 
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The role of IHC with regard to cell differentiation 
 Approximately 70% of salivary gland tumors exhibit myoepithelial 
differentiation, the tumors that do not differentiate into myoepithelium are 
considered to be acinar cell differentiation called the Acinar cell carcinoma. 
The tumors are further classified based on the presence or absence of luminal 
cell differentiation. The luminal cells always show positivity for EMA and 
CEA136. 
The myoepithelial cells usually do not demonstrate glandular formation, 
but occasionally some of the cells which are located around the ductal cells 
exhibit glandular formations. The myoepithelial cells exhibit various cell 
morphology like epithelioid, spindle, plasmacytoid and clear cell types. Hence 
immunohistochemistry analysis is necessary for more accurate diagnosis of 
tumors that show myoepithelial differentiation136. 
Although several markers are available P63 and Cytokeratin is a reliable 
marker in identifying the myoepithelial cells; they are not only positive in 
Renal cell 
carcinoma/CD10 
Negative 
Diagnosis for metastatic renal 
cell carcinoma 
Melan A Negative 
Diagnosis for metastatic 
malignant melanoma 
Lymphoid cell 
marker  
Negative  
Diagnosis for malignant 
lymphoma  
EBER in situ 
hybridization 
Negative  
Positive in lymphoepithelial 
carcinoma 
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neoplastic myoepithelial cells but also positive in basal cell, squamous cells 
and epidermoid cells of Mucoepidermoid carcinoma. It is also essential to 
know the staining patterns of different types of myoepithelial cell to a 
particular marker. 
Spindle cell myoepithelium shows diffuse positivity by α-SMA, MSA 
and Calponine whereas they show only focal positivity in epithelioid and clear 
cell type of myoepithelial cells. Plasmacytoid myoepithelial cells are Calponine 
positive but negative for α-SMA137. 
Role of IHC in Salivary gland tumor exhibiting cribriform pattern 
The tumors that exhibit cribriform pattern are Adenoid cystic carcinoma 
and Salivary duct carcinoma. In addition Basal cell adenoma, Pleomorphic 
adenoma, Epithelial myoepithelial carcinoma, Polymorphous low grade 
adenocarcinoma, Basal cell adenocarcinoma needs to be differentiated. 
a-SMA / Calponine is used to differentiate Adenoid cystic carcinoma 
from Basal cell adenoma . S100 is a useful marker in identifying Polymorphous 
low grade adenocarcinoma (PLGAC) from Salivary duct carcinoma (SDC). 
GFAP is useful in differentiating Pleomorphic adenoma from Polymorphous 
low grade adenocarcinoma, Basal cell adenoma, Epithelial and myoepithelial 
carcinoma136. 
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Benign and malignant counterpart of salivary gland tumors 
Ki67 labeling index is useful in differentiating benign tumors from 
malignant tumors. Ki67 index is high (>10%) in malignant tumors, which is 
(<10%) in benign tumors. They are used in differentiating myoepithelioma 
from myoepithelial carcinoma, Basal cell adenoma from Basal cell 
adenocarcinoma 138. 
Tumors exhibiting clear cell changes 
Tumors like Epithelial-Myoepithelial carcinoma, Mucoepidermoid 
carcinoma, Myoepithelioma, Myoepithelial carcinoma, Acinic cell carcinoma, 
Oncocytoma, Sebaceous adenoma, Clear cell carcinoma, Metastatic renal cell 
carcinoma, Malignant melanoma exhibit clear cell differentiation139.  
Initially it is recommended to use myoepithelial markers like Calponine 
and α-SMA which shows positivity for tumors that arises from myoepithelium 
like Myoepithelioma, Myoepithelial carcinoma and Epithelial- Myoepithelial 
carcinoma; EMA can be used to distinguish Epithelial-Myoepithelial 
carcinoma from Myoepithelioma and Myoepithelial carcinoma  which show 
positivity in the apical portion at the glandular luminal surface.  
Metastatic renal cell carcinoma (RCC) and Malignant melanoma can be 
identified by using RCC, CD10 and Melan-A140. However it is difficult to 
differentiate these tumors only through Immunohistochemistry. 
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Diagnosis of Specific Tumor Type 
Adenoid cystic carcinoma  
C-kit show diffuse expression in Adenoid cystic carcinoma, but in recent 
days its specificity is questionable. Strong MYb immunostaining is a specific 
and useful diagnostic marker for Adenoid cystic carcinoma. However some 
Non Adenoid cystic carcinoma  also show focal positivity in MYb. 
Salivary duct carcinoma: 
20% of tumor show diffuse and strong membrane staining for 
HER2/new. AR and HER2/neu are expected use for molecular targeted 
therapy136. 
                              
                                   
  
  
 
 
 
 
 
METHODOLOGY 
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METHODOLOGY 
This retrospective and prospective study on salivary gland tumors was 
carried out in the department of pathology at Karpaga Vinayaga Institute of 
Medical Sciences, Madhuranthagam from August 2012 to July 2017 for a 
period of five years. The study was conducted on biopsy and excised 
specimens of salivary gland tumors received in department of pathology, 
KIMS. The information regarding the retrospective cases was retrieved from 
laboratory archives. Institutional Ethics Committee approval was obtained. 
       All clinical data like age, gender, location of tumors, duration of 
symptoms was obtained. Routine investigations and radiological examination 
like X–ray, ultrasound, CT Scan reports were reviewed and documented. 
INCLUSION CRITERIA 
Patients with Benign and Malignant Salivary gland tumors. 
EXCUSION CRITERIA 
Patients with inflammatory conditions of salivary gland. Specimens with 
incomplete records and   discordant diagnosis. 
SPECIMEN COLLECTION 
Gross examination of Biopsy and Excised specimen was carried out in 
detail. All the biopsy specimens were well fixed in 10% formalin and then 
processed into paraffin embedded sections and stained with Haematoxylin-
Eosin. All the slides were examined under the light microscope by pathologist 
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for identification of the histomorphological pattern of salivary gland tumors. 
Special stains like PAS was applied to the sections where ever indicated. 
Immunohistochemical markers were also applied, where ever possible, 
to the tissue sections to enhance the accuracy of diagnosis. 
STATISTICAL METHODS 
All data were entered in Microsoft excel and managed using SPSS 
software.  
 
                                                       
 
 
 
                                                   
  
  
 
 
 
 
 
 
RESULTS 
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RESULTS 
Over a period of five years, from September 2012 to August 2017, we 
encountered 57 cases of   Salivary gland tumors in the present study. 
Incidence : 
Table 1: Incidence of Salivary gland Tumors 
Tumors No. of. cases Percentage 
Benign 40 70.1% 
Malignant 17 29.8% 
Total 57 100% 
 
 
 
Out of 57 cases of salivary gland tumors, 40 cases were benign (70.1%) 
and remaining 17 cases were malignant tumors (29.8%).  [Table 1 and   
Chart 1] 
70%
30%
Chart 1: Incidence of Salivary gland Tumors  
BENIGN
MALIGNANT
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Table 2: Frequency distribution of Benign Salivary gland Tumors 
Benign Tumors No .of .cases Percentage 
Pleomorphic Adenoma 33 82.5% 
Warthin`s tumour 3 7.5% 
Basal cell adenoma 2 5% 
Myoepithelioma 2 5% 
Total 40 100% 
 
 
 
Out of 40 benign tumors 33 were Pleomorphic adenoma (82.5%), 3 were 
Warthin`s tumor (7.5%), 2 Basal cell adenoma (5%), and 2 Myoepithelioma 
(5%). [Table 2 and Chart 2]. 
Pleomorphic adenoma was the most commonly observed benign tumor 
in the present study. 
82%
8%
5%
5%
Chart 2: Frequency distribution of   Benign Salivary 
gland Tumors
Pleomorphic Adenoma
Warthin`s tumor
Basalcell adenoma
Myoepithelioma
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Table 3: Frequency distribution of Malignant Salivary gland Tumor   
 
 
Out of 17 malignant tumors encountered in the present study, six were  
Mucoepidermoid carcinoma (35.2%), five Adenoid cystic carcinoma  (29.4%), 
one Polymorphous low grade adenocarcinoma (5.8%), one Carcinoma  
ex-pleomorphic adenoma (5.8%), one Basal cell adenocarcinoma (5.8%) and  
three were Salivary duct carcinoma (17.6%) [Table 3 and Chart 3].  
Mucoepidermoid carcinoma was the most commonly observed malignant 
tumor in the present study.  
35%
29%
6%
6%
6%
18%
Chart 3:  Frequency distribution of Malignant Salivary 
gland Tumor  
Mucoepidermoid carcinoma
Adenoid cystic carcinoma
Polymorphous low grade
adenocarcinoma
Carcinoma ex pleomorphic
adenoma
Malignant Tumors No. of cases Percentage 
Mucoepidermoid carcinoma 6 35.2% 
Adenoid cystic carcinoma 5 29.4% 
Polymorphous low grade adenocarcinoma 1 5.8% 
Carcinoma ex pleomorphic adenoma 1 5.8% 
Basal cell adenocarcinoma 1 5.8% 
Salivary duct carcinoma 3 17.6% 
Total 17 100% 
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Age Incidence: 
Table 4: Age wise distribution of Benign Salivary gland Tumor 
 
 
 
 
 
0 2 4 6 8 10 12 14
10-19.
20-29
30-39
40-49
50-59
60-69
70-79
1
14
11
7
2
1
2
1
1
Chart 4 : Age  wise  distributionof Benign  Salivary 
gland Tumors  
 Myoepithelioma
Basalcell adenoma
Warthin`s tumor
Pleomorphic adenoma
Name of the 
benign 
Neoplasm 
Age 
10-19 20-29 30-39 40-49 50-59 Total 
Pleomorphic 
adenoma 
1 14 11 7 - 33 
Warthin`s 
tumor 
- - 2 1 - 3 
Basal cell 
adenoma 
- 2 - - - 2 
Myoepithelio
ma 
- - 1 - 1 2 
Total 1 16 14 8 1 40 
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The benign tumors were observed widely in the age group between 20 
and 40 years, with the mean age of 31 years. Most commonly observed benign 
salivary gland tumor was Pleomorphic adenoma.  
 
Out of 40 benign tumors encountered in the present study 33 were 
Pleomorphic adenomas making it 82.5%. Majority of the Pleomorphic 
adenomas fell between 3ed and 4th decade of life. 
 
Three out of 40 benign tumors were Warthin`s tumor making it 7.5% of 
benign tumors. It was observed during the 4th decade of life. Basal cell 
adenoma and Myoepithelioma made the least commonly observed benign 
tumors in the present study, making it 5% each. [Table 4 and Chart 4]. 
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Table 5: Age wise distribution of Malignant Salivary gland Tumor 
  
Name of the 
malignant 
neoplasm 
Age 
30-
39 
40-
49 
50-
59 
60-
69 
70-
79 
80-
89 
Total 
Mucoepidermoid  
carcinoma  
- 1 - 1 4 - 6 
Adenoid cystic 
carcinoma  
1 1 1 1 1 - 5 
Polymorphous low 
grade 
adenocarcinoma  
- - - 1 - - 1 
Carcinoma ex 
pleomorphic 
adenoma  
- - 1 - - - 1 
Basal cell 
adenocarcinoma 
- - - 1 - - 1 
Salivary duct 
carcinoma  
- 1 1 1 - - 3 
Total 1 3 3 5 5 - 17 
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Malignant salivary gland tumors were more commonly observed  
between 5th and 8th decade with the mean age of  59 years. The most commonly 
observed malignant salivary gland tumor was Mucoepidermoid carcinoma.  
We encountered 6 cases of Mucoepidermoid carcinoma out of 17 cases 
of malignant tumors in the present study, making it 35.2% of all malignant 
tumors. It was followed by Adenoid cystic carcinoma, 5 out of 17 malignant it 
29.4% of all malignant tumors. 
We also encountered three cases of Salivary duct carcinoma (17.6%). 
The least commonly observed malignant tumors in the present study were 
Basal cell adenocarcinoma, Polymorphous low grade adenocarcinoma and 
Carcinoma ex-Pleomorphic adenoma. [Table 5 and Chart 5] 
0 1 2 3 4
20-29
30-39
40-49
50-59
60-69
70-79
Chart 5:  Age wise distribution of Malignant Salivary 
gland Tumor 
salivary duct carcinoma
Basalcell adenocarcinoma
Carcinoma ex pleomorphic
adenoma
Polymorphous low grade
adenocarcinoma
Adenoid cystic carcinoma
Mucoepidermoid carcinoma
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Table 6: Gender wise distribution of Benign Salivary gland tumors 
 
 
 
Most of the benign tumors were predominantly observed in female 
population. 
Out of 40 benign tumors encountered in the present study 28 were 
observed in female population making it (70%) and 12 were observed in male 
population making it (30%). [Table 6 and Chart 6]. 
  
Pleomorphic
adenoma
Warthin`s tumor Basalcell
adenoma
Myoepithelioma
9
3
24
2 2
Chart 6 : Gender wise distribution of Benign Salivary 
gland Tumors  
Male Female
Neoplasm Male Female Total 
Pleomorphic adenoma 9 24 33 
Warthin`s tumor 3 - 3 
Basalcell adenoma  - 2 2 
Myoepithelioma  - 2 2 
Total  12 28 40 
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Table 7: Gender wise distribution Malignant Salivary gland Tumors 
  
Malignant Male Female Total 
Mucoepidermoid carcinoma  4 2 6 
Adenoid cystic carcinoma 2 3 5 
Polymorphous low grade 
adenocarcinoma  
- 1 1 
Carcinoma ex pleomorphic 
adenoma  
- 1 1 
Basal cell adenocarcinoma - 1 1 
Salivary duct carcinoma  - 3 3 
Total 6 11 17 
 
       
 
In the present study, most of the malignant salivary gland tumors were 
observed in female population. Out of 17 malignant salivary gland  tumors 11 
were observed in female population  making it 64%  and 6 were observed  in 
male population making it 35.2%.[Table 7 and Chart 7 ]. 
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Chart 7: Gender wise distribution of Malignant 
Salivary gland Tumors 
Male
Female
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Table 8: Site wise distribution of Salivary gland Tumors 
  
Neoplasm Parotid Submandibular Sublingual 
Minor 
SG 
Total 
Pleomorphic 
adenoma 
22 7 4 - 33 
Warthin`s tumor 3 - - - 3 
Basal cell 
adenoma 
2 - - - 2 
Myoepithelioma 2 - - - 2 
Mucoepidermoid 
carcinoma 
4 1 - 1 6 
Adenoid cystic 
carcinoma 
4 - - 1 5 
Polymorphous 
low grade 
adenocarcinoma 
- - - 1 1 
Carcinoma ex 
pleomorphic 
adenoma 
1 - - - 1 
Basal cell 
adenocarcinoma 
1 - - - 1 
Salivary duct 
carcinoma 
3 - - - 3 
Total 42 8 4 3 57 
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Chart 8: Site wise distribution of salivary gland tumor 
 
 
 
Most commonly affected Salivary gland in the present study was 
parotid. Out of 57 neoplastic lesion 42 were observed in parotid, 8 were 
observed in submandibular gland, 4 were observed in Sublingual gland and 3 
were observed in minor salivary gland. [Table 8 and Chart 8 ]. 
  
22
3
2 2
4 4
1 1
3
7
1
4
0
5
10
15
20
25
Pleomorphic
adenoma
Myoepithelioma Polymorphous low
grade
adenocarcinoma
Salivary duct
carcinoma
Parotid Submandibular Sublingual gland Minor salivary gland
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Table 9: Site wise distribution of Benign Salivary gland Tumors 
Neoplasms Parotid Submandibular Sublingual 
Minor 
SG 
Total 
Pleomorphic 
adenoma 
22 7 4  33 
Warthin`s tumour 3 - - - 3 
Basal cell adenoma 2 - - - 2 
Myoepithelioma 2 - - - 2 
Total 29 7 4  40 
 
     
The most commonly involved salivary gland by the benign tumors was 
parotid gland. Out of 40 benign tumors 29 were observed in parotid gland. The 
submandibular salivary gland showed involvement by 7 benign tumors. The 
least commonly involved salivary gland was minor salivary gland. [Table 9, 
Chart 9]. 
0 5 10 15 20 25
Parotid
Submandibular
Sublingual gland
22
7
4
3
2
2
Myoepithelioma Basal cell adenoma Warthin`s tumor Pleomorphic adenoma
Chart 9: Site wise distribution of Benign   
Salivary  gland Tumors
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Table 10: Site wise distribution of Malignant Salivary gland Tumors 
 
Malignant Parotid Submandibular Sublingual 
Minor 
SG 
Total 
Mucoepidermoid  
carcinoma 
4 1 - 1 6 
Adenoid cystic 
carcinoma  
4 - - 1 5 
Polymorphous low 
grade adenocarcinoma  
- - - 1 1 
Carcinoma ex 
pleomorphic adenoma  
1 - - - 1 
Basal cell 
adenocarcinoma  
1 - - - 1 
Salivary duct carcinoma  3 - - - 3 
Total  13 1 - 3 17 
 
Chart  10: Site wise distribution of  Malignant Salivary gland Tumors : 
 
The most commonly involved salivary gland by the malignant tumors 
was parotid gland.  Out of 17 malignant tumors 13 were observed in parotid 
gland. The minor salivary gland showed involvement by 3 malignant tumors. 
The least commonly involved salivary gland was sublingual glands. [Table 10, 
Chart 10]. 
0 1 2 3 4
Mucoepidermoid carcinoma
Adenoid cystic carcinoma
Polymorphous low grade…
Carcinoma ex pleomorphic…
Basalcell adenocarcinoma
Salivary duct carcinoma
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Sublingual
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Table 11:   P63 Expression in salivary gland tumors: 
Tumors 
No. of 
cases 
No. of. 
Positive 
cases 
IHC SCORE 
Cellular 
location Weak Moderate Strong 
Pleomorphic 
adenoma 
33 33 - 3 30 
Myoepithelial 
cells 
Mucoepidermoid 
Carcinoma  
6 6 - 2 4 
Intermediate, 
Squamous, 
Clear cells 
Adenoid Cystic 
Carcinoma  
5 5 1 4 - 
Abluminal 
cells 
Carcinoma ex 
Pleomorphic 
Adenoma 
1 1 - - 1 
Malignant 
Squamous 
epithelium 
 
Interpretation of P63 immunostaining: 
Immunostaining was scored as below;  
Negative : less than 10% of tumor nuclear stained. 
Weakly positive: 10-25% of tumor nuclear stained.  
Moderately positive: 26-75% of tumor nuclear stained. 
Strongly positive : 76-100% of tumor nuclear stained.  
 The grading was performed semiquantitatively by double blinded  
pathologists. 
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 The normal salivary tissue adjacent to the tumor shows P63 expression 
in the nuclei of basal cells and myoepithelial cells. 
In the present study all 33 (100%) cases of Pleomorphic adenoma were 
P63 positive of which 30  showed strong diffuse nuclear reactivity in 
myoepithelial cells and  three  showed weak reactivity.(Fig: 14) 
 Out of  six cases of Mucoepidermoid carcinoma in the present study,  
four  showed strong nuclear reactivity in intermediate, squamous and clear 
cells, while two showed weak positivity.(Fig:15) 
Out of five cases of Adenoid cystic carcinoma four cases showed 
moderate positivity in the nuclei of tumor cells, while one case showed weak 
positivity.(Fig:17) 
A solitary case of Carcinoma ex Pleomorphic adenoma in the present 
study showed strong nuclear positivity in the malignant squamous cells. 
(Fig: 21) 
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Table 12:  CK-14 Expression in salivary gland tumors 
Tumors 
No.of 
cases 
No.of. 
Positive 
cases 
IHC SCORE 
Cellular 
location Weak Moderate Strong 
Mucoepidermoid 
Carcinoma 
6 6 - - 6 
Intermediate 
Squamous, 
Clear cells 
Adenoid Cystic 
Carcinoma 
5 5 - 5 - 
Abluminal 
Cells 
Carcinoma ex 
Pleomorphic 
Adenoma 
1 1 - - 1 
Malignant 
Squamous 
epithelium 
Salivary Duct 
Carcinoma  
3 3 3 - - 
Squamous 
cells 
 
In normal salivary gland all four types of cells are Pan-Cytokeratin (CK) 
positive. In the present study all six cases of Mucoepidermoid carcinoma 
showed strong cytoplasmic CK-14 positivity in intermediate, squamous and 
clear tumor cells. (Fig : 16) 
 All five cases of Adenoid cystic carcinoma showed moderate 
cytoplasmic positivity in tumor cells. (Fig: 18). All three cases of Salivary duct 
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carcinomas in the present study showed weak cytoplasmic positivity for CK-
14. (Fig  : 20). 
 
 Solitary case of Carcinoma ex Pleomorphic Adenoma in the present 
study showed strong cytoplasmic positivity in the tumor cells. (Fig : 22)  
 
HER 2/ neu expression: 
Normal salivary gland parenchymal cells are negative to weakly positive 
in ductal cells for HER2/neu. However it is highly over expressed in Salivary 
duct carcinoma136.In the present study all three salivary duct carcinomas 
expressed diffuse and strong membrane positivity in carcinoma cells. (Fig : 19) 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
IMAGE GALLERY   
  
I 
 
 
Figure 1:  Pleomorphic Adenoma showing epithelial and  
myoepithelial cell proliferation in a chondromyxoid stroma   
[HE,X100] 
 
 
 
Figure 2:  Warthin`s Tumor showing cystic and papillary  
projections lined by the double layered oncocytic epithelium  
in a lymphoid stroma [HE, X400] 
II 
 
 
Figure 3: Myoepithelioma showing spindle shape myoepithelial cells                               
[HE, X400] 
 
 
 
Figure 4: Myoepithelioma showing plasmacytoid myoepithelial cells 
[HE, X400] 
III 
 
 
Figure 5: Basal cell Adenoma showing tubules lined by  
basaloid cells with peripheral palisading. [HE,X 100] 
 
 
 
 
Figure 6: Low grade Mucoepidermoid carcinoma showing glandular  
structures lined by mucous secreting cells. [HE, X 400] 
IV 
 
 
Figure 7: Adenoid cystic carcinoma showing  proliferation of  
tumor cells in cribriform growth pattern enclosing  
basophilic material [HE, X100] 
                                     
 
 
 
Figure 8: Adenoid cystic carcinoma showing perineural invasion                  
[HE, X100] 
V 
 
 
Figure 9:  Carcinoma ex pleomorphic adenoma showing both  
benign and malignant components [HE, X400] 
 
 
 
 
Figure 10:  Polymorphous low grade Adenocarcinoma showing  
tumor cells arranged in cord like pattern  [HE, X400] 
VI 
 
 
 
Figure 11:  Salivary duct carcinoma showing highly  
Pleomorphic tumor cells lining the ductal structures with  
comedo necrosis [HE, X400] 
 
 
 
 
Figure 12: Basal cell Adenocarcinoma showing tubular structures  
arranged in trabecular pattern  [HE,X100] 
VII 
 
 
Figure 13: Mucoepidermoid carcinoma –PAS Stain:  
Positive for mucin. 
 
 
 
 
Figure 14: P63 expression in Pleomorphic Adenoma -  
Nuclear positivity 
VIII 
 
 
Figure 15: P63 expression in Mucoepidermoid carcinoma– 
Nuclear positivity. 
 
 
 
Figure 16: CK-14 expression in Mucoepidermoid carcinoma–    
Cytoplasmic positivity 
IX 
 
 
Figure 17 :  P63 expression in Adenoid cystic carcinoma –  
Nuclear positivity. 
 
 
 
Figure 18 :  CK-14 expression in Adenoid cystic carcinoma –  
Cytoplasmic positivity 
 
X 
 
 
Figure 19:   Her 2 neu expression in salivary duct carcinoma – 
Membrane positivity. 
 
 
 
 
 
 
 
Figure 20 :  CK-14 expression in salivary duct carcinoma-  
Weak cytoplasmic positivity 
XI 
 
 
Figure 21  :  P63 expression in carcinoma ex pleomorphic adenoma –  
Nuclear Positivity 
 
 
 
 
 
Figure 22 :  Cytokeratin expression in carcinoma ex pleomorphic adenoma  
– Cytoplasmic positivity 
  
 
 
 
 
 
DISCUSSION 
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DISCUSSION 
 
Salivary gland tumors exhibit a diverse group of benign and malignant 
tumors which show multifaceted clinical pictures, variable morphological 
architecture with unpredictable prognostic status. 
 
The present study was carried on 57 consecutive cases of various types 
of salivary gland neoplasms.  
 
The main aspects considered in present study are the histomorphological 
findings made out by light microscopic examination and also by using special 
stains where ever required, the incidence rate of the salivary gland tumors in 
different age groups and to observe Immunohistochemical reactions exhibited 
by the tumor cells of different salivary gland neoplasms. 
 
Incidence: 
Out of 57 cases encountered in the present study 40 were benign 
(70.1%) and remaining 17 cases were malignant (29.8%).  
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Table 11 :  Incidence of Salivary gland Tumors in various studies 
  
The result observed in the present study is in correlation with Janu 
devi.et al141,   Juan Araya.et al142, Rajesh Sing.et al143, M.S.Gill.et al144, Alpana 
Banerjee.et al145 and Nepal.et al146, irrespective of total number of cases. The 
benign lesions were more common followed by malignant lesions. 
The benign neoplasms outnumber the malignant ones. Out of 57 total 
salivary gland neoplasms 40 were benign (70.1%) and 17 were malignant 
(29.8%). This observation is also in correlation with those quoted by Janu 
devi.et al141, Juan Araya.et al142, Rajesh Sing.et al143, M.S.Gill.et al144, Alpana 
Banerjee.et al145 and Nepal.et al146. 
M.S.Gill et al144 who studied 379 neoplasms of salivary gland found 277 
(73.0%) benign neoplasms and 102 (26.9%) malignant neoplasms.  
Similarly Juan Araya et al142 who studied 279 of salivary gland 
neoplasm found 196 benign neoplasms making it 70.2% and 83 malignant 
neoplasms making it 29.7%. 
S.
N 
Study Place Year 
Total 
case 
Benign Malignant 
1 Janu Devi et al 141 Assam 2 84 57(67.8%) 27(32.2%) 
2 
Juan Araya  
et al142 
Valparaiso 
chile 
11 279 196(70.2%) 83(29.7%) 
3 
Rajesh singh  
et al143 
Manipur 
 
10 104 56(53.8%) 
22(21.1%) 
 
4 M.S.Gill et al144 Karachi 8 379 277(73.0%) 102(26.9%) 
5 
AlpanaBanerjee 
et al145 
Tripura 7 46 37(80.4%) 9(19.5%) 
6 Nepal et al146 Nepal 5 51 41(80.3%) 10(19.6%) 
7 Present study kanchipuram 5 57 40(70.1%) 17(29.8%) 
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Table 12:  Distribution of Benign Salivary gland Tumors 
 
Benign tumors 
Shahidaniaz
i.et.al147 
ShilpaH 
Gandhi.et.al148 
Shafkat Ahrnad 
et.al149 
Present 
study 
Pleomorphic 
adenoma (PA) 
146(90.1%) 33(78.5%) 73(85.8%) 33(82.5%) 
Warthin tumour 8(4.9%) 8(19.4%) - 3(7.5%) 
Basal Cell 
adenoma 
1 1 - 2 
Myoepithelioma 1 - 1 2 
Oncocytoma 1 - - - 
Sebaceous 
Lymphadenoma 
1 - - - 
Lipoma 3 - 5 - 
Hemangioma 1 - 2 - 
lymphangioma - - 2 - 
Neurofibroma - - 1 - 
cystadenoma - - 1 - 
Total Benign 
Tumours 
162 42 85 40 
 
Out of 40 benign neoplasms in the present study, 33 were Pleomorphic 
adenoma making it 82.5% of  total benign tumors. 
Thus Pleomorphic adenoma was the most commonly observed benign 
tumor in the present study. Similar observations were quoted by  
Shahidaniazi.et.al147,  Shilpa.H.Gandhi.et.al148,  Shafkat Ahrnad et.al149. 
Out of 162 benign tumors reported by Shahidaniazi.et.al147, 146 were 
Pleomorphic adenoma making it 90.1%, out of 42 benign tumors by Shilpa .H. 
Gandhi.et.al148  33 were Pleomorphic adenoma making it 78.5% and out of  85 
benign tumor reported by  Shafkat Ahrnad et.al149 73 were Pleomorphic 
adenoma making it 85.8%. Our observations in the present study are 
comparable with all above three studies. 
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Table 13: Distribution of Malignant Salivary gland Tumors 
 
Malignant tumors 
Khandekar. et 
al150 
Shashikala et 
al151 
Present study 
Mucoepidermoid carcinoma 
(MEC) 
11(50.0%) 5(71.4%) 6(35.2%) 
Adenoid Cystic Carcinoma 8(36.3%) - 5(29.4%) 
Acinic Cell Carcinoma - 1 - 
Polymorphous Low Grade 
Adenocarcinoma 
- - 1 
Salivary duct carcinoma - - 3 
Basalcell adenocarcinoma - - 1 
Carcinoma ex pleomorphic 
adenoma 
- 1 1 
Squamous cell carcinoma 2 - - 
Adenocarcinoma 
 
1 - - 
Total malignant tumor 22 7 17 
 
Out of 17 malignant neoplasms in the present study, six were 
Mucoepidermoid carcinoma making it 35.2% of total malignant tumors. 
Thus Mucoepidermoid carcinoma was the most commonly observed 
malignant tumor in the present study. Similar observations were quoted by 
Khandekar. et al150,  Shashikala. et al151. 
Out of 22 malignant tumor reportred by Khandekar. et al150 11 were  
Mucoepidermoid carcinoma making it 50.0%  and out of 7 malignant tumor 
reported by Shashikala. et al151  5 were Mucoepidermoid carcinoma making  
it 71.4%. Our observations in the present study are comparable with all above 
studies. 
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Age incidence: 
 
Table 14  :   Age incidence of Salivary gland Tumors 
 
All the salivary gland tumors were observed between a wide range age 
group starting from 3rd decade of life to 8th decade. This finding is similar to 
Dave P.N.et al152, Shree devi S.Bobati.et al153,Shrestha.S.et al154, Dhanamjeya 
Rae Teeda .et al155,Shazia Bashir.et al156. 
The youngest patient in the present study was 17 years female and the 
oldest was 76 years. The youngest had Pleomorphic adenoma while the oldest 
had Mucoepidermoid carcinoma. The maximum number of salivary gland 
tumors were encountered during 3rd decade of life and were benign in nature 
which is comparable to the finding noted by Dave.P.N et al152.  Malignant 
salivary gland tumors were more commonly observed between 5th and 8th 
decade with the mean age of 59 years  in the present study. Dave P.N.et al152, 
Shree devi S.Bobati.et al153, Shrestha.S.et al154, Dhanamjeya Rae Teeda.et al155, 
Shazia Bashir.et al156, also encountered the similar results. 
 
Study Benign Malignant 
Dave P.N et al152 3ed  decade 5th  decade 
Shree devi S. Bobati et al153 4th decade 6th decade 
Shrestha .S et al154 4th decade 5th decade 
Dhanamjeya Rae Teeda et al155 4th decade 6th decade 
Shazia Bashir et al156 4th decade 5th decade 
Present study 3nd  and 4th  decade 5th and 8th  decade 
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Gender wise distribution of salivary gland tumors 
Table 15 : Gender wise distribution of  Salivary gland Tumors 
Tumors 
Samina zaman et al157 Present study 
Male Female Male Female 
Pleomorphic adenoma 16 27 9 24 
Warthin`s tumor 1 1 3 - 
Basalcell adenoma 1 1 - 2 
Myoepithelioma 1 2 - 2 
Oxyphilic adenoma - 1 - - 
Mucoepidermoid 
carcinoma 
4 1 4 2 
Adenoid cystic carcinoma 1 1 2 3 
Acinic cell carcinoma - 3 - - 
Polymorphous low grade 
adenocarcinoma 
- 1 - 1 
Carcinoma ex pleomorphic 
adenoma 
1 - - 1 
Basalcell adenocarcinoma - - - 1 
Epithelial-myoepithelial 
carcinoma 
1 - - - 
Salivary duct  carcinoma - - - 3 
Total 26 38 18 39 
 
In the present study majority of benign and malignant salivary gland 
tumors were observed predominantly in female population with the female : 
male ratio 2:1, which is comparable to the findings quoted by Samina zaman.  
et al157.Out of 33 Pleomorphic adenomas in the present study, 24 were found in 
females and 9 in males  making it 3:1.  
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Table 16 : Site wise distribution of Salivary gland Tumors 
Study Parotid 
Submandibular 
gland 
Sublingual 
gland 
Minor 
salivary 
gland 
Total 
Krishnaraj 
Subhashraj  et al158 
414 116  150 680 
Lakshmibai B 
Mallappa et al159 
17 8 3  28 
Maj T Chatter jee  
et al160 
243 30  14 287 
Kirti N. Jaiswal  
et al161 
68 13  15 96 
Subhashini Bandar  
et al162 
33 8  7 48 
Present study 42 8 4 3 57 
 
The most commonly affected salivary gland by neoplastic lesion was 
parotid in the present study followed by submandibular salivary gland  and 
minor salivary glands. 
Out of 57 salivary gland tumors encountered in the present study 42 
cases were observed involving  parotid gland (73.6%) and 8 cases were 
involving submandibular gland (14.3%). The sublingual and minor salivary 
gland were least affected. These findings are comparable with other studies 
quoted by Krishnaraj Subhashraj et al158, Lakshmibai B Mallappa et al159, Maj 
T Chatter jee et al160, Kirti N. Jaiswal et a1161, Subhashini Bandar et al162. 
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Out of 40 benign tumors 29 were observed in parotid gland (72.5%), 7 
in submandibular gland (17.5%%)and 4 in sublingual gland (10%). Similarly 
out of 17 cases of malignant tumors 13 were observed in parotid (76.4%), three 
cases were observed in  Minor salivary gland (17.6%), one was observed in 
submandibular gland (6.2%). 
Immunohistochemical analysis of salivary gland tumors 
In the present study we examined the expression of P63, CK-14 and 
HER2/neu in various salivary gland tumors to assess their possible role in the 
diagnosis and differential diagnosis of these tumors. 
P63 
P63 is a member of the P53 family of transcription factors. 
Myoepithelial cell differentiation occurs to variable degrees in Pleomorphic 
adenomas, Adenoid cystic carcinomas, Polymorphous low grade 
adenocarcinomas and Epithelial- Myoepithelial carcinoma. Intermediate cells 
of Mucoepidermoid carcinoma also demonstrate characteristics of modified 
myoepithelial cells163. 
In the present study all the 33 cases (100%) of Pleomorphic adenoma 
were P63 positive of which 30 showed strong diffuse nuclear reactivity in 
myoepithelial cells and three showed weak reactivity. 
Out of six cases of Mucoepidermoid carcinoma in the present study,  
four showed strong nuclear reactivity in intermediate, squamous and clear cells, 
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while two showed weak positivity. These result support those of Ralph and 
Douglas163 who reported strong positive nuclear staining for P63 in 100%  of 
examined MEC. Seethala et al164 and Bilal et al165 also reported same results in 
their studies. 
Out of five cases of Adenonoid cystic carcinoma four cases showed 
moderate positivity in the nuclei of tumor cells, while one case showed weak 
positivity, these results are comparable to the study of Seethala  et al 164 and 
Bilal et al165. 
A solitary case of Carcinoma ex Pleomorphic adenoma in the present 
study  showed strong nuclear positivity for P63 in the malignant squamous 
cells.  
Cytokeratin (CK-14)  
In the present study all six cases of Mucoepidermoid carcinoma showed 
strong cytoplasmic CK-14 positivity in intermediate, squamous and clear tumor 
cells. 
All five cases of Adenoid cystic carcinoma showed moderate 
cytoplasmic positivity in tumor cells. 
Solitary case of Carcinoma ex Pleomorphic Adenoma in the present 
study showed strong cytoplasmic positivity in the tumor cells. 
 All three cases of Salivary duct carcinomas in the present study showed 
weak cytoplasmic positivity  for CK-14  
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Our results on CK14 positivity in various salivary gland tumors tally 
with those observations quoted by Toshitaka Nagao et.al136. 
HER2/neu expression: 
Salivary duct carcinoma is a high grade malignancy and displays similar 
histological appearances to ductal breast carcinoma. 
The estrogen receptor and progesterone receptor are not detected in most 
salivary duct carcinomas. This finding is some time useful for distinguishing 
this tumor from breast cancer metastasis. However more than 20% of  salivary 
duct carcinomas show diffuse and strong membranous staining for HER2/neu 
that correlates with aggressiveness of the tumor136. 
In present study all three salivary duct carcinomas encountered, showed 
strong immunoreactivity for HER2/neu. Our findings are in corroboration with 
the observations made my Toshitaka Nago et al136 .  
In conclusion, we tried in the present study to clarify the possible role of 
P63, CK-14 and HER2/neu in the diagnosis and differential diagnosis between 
various types of salivary gland tumors.  
We found that P63, which is a nuclear marker is positive in tumors like 
Pleomorphic adenoma, Mucoepidermoid carcinoma, Adenoid cystic carcinoma 
and Carcinoma ex-pleomorphic adenoma. 
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 CK-14 , which is a cytoplasmic marker is positive in Mucoepidermoid 
carcinoma, Adenoid cystic carcinoma, Carcinoma ex pleomorphic adenoma 
and  Salivary duct carcinoma. 
HER2/neu shows diffuse and strong membranous staining in salivary 
duct carcinoma. 
Limitations of this study included a limited number of available cases of 
each tumor type and missing of some tumor types such as Acinic cell 
carcinomas due to its relatively infrequent occurrence. Hence we recommend 
further studies for studying the immnunohistochemical expression of p63 and 
CK-14 in other types of salivary gland tumors not encountered in the present 
study. 
 
                                   
                          
             
                             
 
 
                                         
  
 
 
 
 
SUMMARY  
AND  
CONCLUSION 
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SUMMARY AND CONCLUSION 
 In the present study we analyzed the incidence, distribution and 
histomorphological patterns of Salivary gland Tumors over a period of five 
years from September 2012 to August 2017 in the department of pathology 
at Karpaga Vinayaga Institute of Medical Sciences and Research Institute 
Centre. 
 Out of 57 salivary gland tumors studied in the present study 40 were benign 
making it 70.1% and 17 were malignant making it to 29.8% of the total 
Salivary gland Tumors. 
 Pleomorphic Adenoma was the most commonly observed benign tumor. 
Out of 40 benign tumors 33 were Pleomorphic adenomas making it 82.5% 
of all the benign tumors. 
 Mucoepidermoid carcinoma was the most commonly observed malignant 
tumor. Out of 17 malignant tumors 6 were Mucoepidermoid carcinomas 
making it 35.2% of all the malignant tumors. 
 Most of the benign tumors were found between the age group of 20 to 40 
years with the mean age of 31 years and most of the malignant tumors were 
found between the age group of 40 to 70 years with the mean age of  
59 years. 
 Female gender was the most commonly affected gender by both benign and 
malignant salivary gland tumors. Out of 57 cases of salivary gland tumors 
39 were females and 18 were males making it a ratio of   2:1. 
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 Parotid was the most commonly affected salivary gland irrespective of the 
nature of the neoplasm. Out of 57 salivary gland neoplasms 42 were 
observed in parotid gland (73.6%), 8 were observed in submandibular 
salivary  gland (14%), 4 neoplasms were observed in sublingual gland (7%)   
and 3 were observed in minor salivary gland ( 5.2%) . 
 In the present study we tried to clarify the possible role of P63, CK-14 and 
HER2/neu in the diagnosis and differential diagnosis between various types 
of salivary gland tumors.  
 We found that P63, which is a nuclear marker, is always positive in 
diagnosing Pleomorphic adenoma, Mucoepidermoid carcinoma, Adenoid 
cystic carcinoma and Carcinoma ex-pleomorphic adenoma. 
 CK-14, which is the cytoplasmic myoepithelial marker, is always positive 
in Mucoepidermoid carcinoma, Adenoid cystic carcinoma, Carcinoma ex 
pleomorphic adenoma and Salivary duct carcinoma. 
 HER2/neu shows diffuse and strong membranous staining in salivary duct 
carcinoma. 
 Limitations of this study included a limited number of available cases of 
each tumor type and missing of some tumor types such as Acinic cell 
carcinomas due to its relatively infrequent occurrence. Hence we 
recommend further studies for all the immnunohistochemical markers in all 
the types of salivary gland carcinomas. 
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ANNEXURE A 
DATA COLLECTION FORM 
 
 
NAME :                                           DATE: 
AGE:  
I.P.NO: 
WEIGHT:  
PARITY : 
 
CHIEF COMPLAINTS : 
 
PAST MEDICAL HISTORY:  
 
GROSS  FINDINGS: 
 
HISTOPATHOLOGICAL FINDING : 
 
                         
                          
  
ANNEXURE B 
STAINING TECHNIQUE 
Hematoxylin and eosin (H&E) 
Procedure  
1. Bring sections to water  
2. Stain with harris hematoxylin for 2- 3 minutes  
3. Wash with running tap water  
4. Differentiate in 1% acid alcohol 
5. Wash and blue with running tap water 
6. Counter stain with aqueous eosin for 2 minutes  
7. Dehydrate with absolute alcohol (2-3changes) 
8. Clear with 2-3changes of xylene 
9. Mount using  Dibutyl phthalate polystyrene xylene (Dpx) 
 
Result   
Nucleic acid – blue  
Cytoplasm – pink  
 
 
 
 
ANNEXURE C :  PERIODIC ACID SCHFF`S STAINING(PAS) 
1. Cut paraffin sections 4 to 5 microns thick 
2. Deparaffinise using xylene for 5 minutes 
3. Take to alcohol two chages each 5 minutes  
4. Bring sections to water 
5. Periodic acid for 5 to 10 minutes  
6. Wash thoroughly in water  for 1minute. 
7. Place the sections in Schiff`s reagent for 15 minutes. 
8. Wash the sections in running water for 10 minute. 
9. Counter stain in Harris haematoxyline   for half minute  
10. Wash sections well to blue the haematoxyline. 
11. Dehydrate with 95% and absolute alcohol, clear with Xylene and         
mount the sections  
 
 
 
 
 
 
 
 
 
ANNEXURE D 
FLOW CHART FOR IMMUNOHISTOCHEMISTRY 
1.Cut 3mm sections on charged slides and incubated at 60-70 C for 1hour 
2.Deparafinized by 2 changes of xylene 5minutes each. 
3.Hydrate through descending grade of alcohol as follows: 
Absolute alcohol –two changes , 5 minutes each 
           90% alcohol -5 minutes 
           70% alcohol – 5minutes  
           Wash in distilled water , two changes, 2minutes each  
4.Antigen retrival for 15-20 minutes in MERS. Ph of retrival buffer may be 
either 6,8 or 9.5acorrding to the marker. 
5.Wash in distilled water, two changes, 2minutes each. 
6.Wash in Triss buffer solution for 2minutes. 
7.Do endogenous peroxidase blocking by adding H2O2 on the section, keep for    
   5minutes. 
8.Wash in the wash buffer for 2 minutes , twice. 
9. Add primary antibody and keep for  30 minutes in a moist chamber . then          
wash in wash buffer2 times, 2minutes each.  
10. Add polyexcel Target binder reagent and keep for 15 minutes. Wash in two 
changes. 
11. Add polyexcel HRP and incubate for 15 minutes. Wash with buffer , 2 
minutes two changes. 
12.Add working DAB chromogen (1ml DAB Buffer +1 drop of DAB 
chromogen, mix well) and keep for 2-5, then wash in distilled water . 
13. counter stain with haematoxlinn for 30seconds , wash with water. 
14.Dehydrate , clear and mount the slide . 
  
ANNEXURE – E 
LIST OF ABBREVIATIONS 
 
H&E      - Haematoxylin and Eosine     
IHC      - Immunohistochemistry   
MEC     - Mucoepidermoid carcinoma   
EMC      - Epithelial –myoepithelial carcinoma 
PLGAC     - Polymorphous low-grade  
      adenocarcinoma    
SDC      - Salivary duct carcinoma   
AdCC     - Adenoid cystic carcinoma  
LCC      - Low-grade cribriform  
      Cystadenocarcinoma   
CEA      - Carcinoembryonic antigen  
EMA      - Epithelial membrane antigen  
SMA      - Smooth muscle actin    
GFAP     - Glial fibrillary acidic protein   
CK      - Cytokeratin      
MSA      - Muscle specific antigen   
AR      - Androgen receptor     
                                  
  
ANNEXURE – F 
LIST OF TABLES 
TABLE 
NO`S 
 
DESCRIPTION OF TABLE 
 
1 Incidence of Salivary gland Tumors 
2 
Frequency distribution of Benign Salivary gland Tumors 
 
3 
Frequency distribution of Malignant Salivary gland Tumor 
 
4 
Age wise distribution of Benign Salivary gland Tumor 
 
5 
Age wise distribution of Malignant Salivary gland Tumor 
 
6 
Gender  wise distribution of  Benign Salivary gland tumors 
 
7 
Gender wise distribution Malignant Salivary gland Tumors 
 
8 
Site wise distribution of Salivary gland Tumors 
 
9 
Site wise distribution of  Benign  Salivary gland Tumors 
 
10 
Site wise distribution of  Malignant Salivary gland Tumors 
 
11 
P63 Expression in salivary gland tumors 
 
12 
CK-14  Expression in salivary gland tumors 
 
 
 
 
 
 
ANNEXURE – G 
LIST OF CHART 
CHART 
NO`S 
                      DESCRIPTION OF CHART 
1 Incidence of Salivary gland Tumors  
2 Frequency distribution of Benign Salivary gland Tumors    
3 Frequency distribution of Malignant Salivary gland Tumors 
4 Age wise distribution of Benign Salivary gland Tumors 
5 Age wise distribution of Malignant Salivary gland Tumors 
6 Gender  wise distribution of  Benign Salivary gland tumors 
7 Gender wise distribution Malignant Salivary gland Tumors 
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ANNEXURE – H 
LIST OF FIGURES 
Figure 
No`s 
                       DESCRIPTION OF FIGURE`S 
1 Pleomorphic Adenoma 
2  Warthin`s Tumor 
3 Myoepithelioma- spindle variants 
4 Myoepithelioma- plasmacytoid variant  
5 Basal cell Adenoma 
6 Low grade Mucoepidermoid carcinoma 
7 Adenoid cystic carcinoma 
8 Adenoid cystic carcinoma- perineural invasion 
9 Carcinoma ex pleomorphic adenoma   
10 Polymorphous low grade Adenocarcinoma 
11 Salivary duct carcinoma 
12 Basal cell Adenocarcinoma 
13 Mucoepidermoid carcinoma –PAS Stain 
14 P63 expression in Pleomorphic Adenoma –Nuclear positivity 
15 P63 expression in Mucoepidermoid carcinoma–Nuclear positivity 
16 
CK-14 expression in Mucoepidermoid carcinoma–   Cytoplasmic 
positivity 
17 P63 expression in Adenoid cystic carcinoma – Nuclear  positivity  
18 
CK-14 expression in Adenoid cystic carcinoma – Cytoplasmic 
positivity  
19 
 Her 2 neu expression in salivary duct carcinoma -Membrane     
 positivity 
20 
CK-14 expression in salivary duct carcinoma- weak     
 cytoplasmic positivity 
21 
P63 expression in carcinoma ex pleomorphic adenoma – Nuclear 
Positivity 
22 
Cytokeratin expression in carcinoma ex pleomorphic adenoma –  
Cytoplasmic positivity                                             
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